新疆维吾尔族食管鳞癌蛋白质图谱研究
|
摘要
食管癌是消化系统常见的恶性肿瘤之一。中国是食管癌高发国家,鳞癌约占我国食管癌总数的80%。食管癌流行病学特征除了显著的地域分布差异之外,民族分布差异亦是其主要的特征之一。食管癌的发生在新疆有着显著的地域性和民族聚集性,提示新疆食管癌的发生受环境和遗传因素共同影响。维吾尔族是新疆的主体民族,但是已有的研究对新疆维吾尔族食管癌的相关研究较少。
目前仍然缺乏食管癌的早期诊断方法,大部分食管癌患者确诊时已属中晚期,治疗的效果欠佳。手术治疗是食管癌治疗的主要方法,食管癌患者手术后死亡的主要原因是肿瘤复发和转移,肿瘤淋巴结转移是影响食管癌预后的重要因素之一。目前对手术前有无淋巴结转移判断存在不准确的问题,给手术和治疗方式选择带来了一定的盲目性。提高患者手术前TNM分期的准确率,特别是提高对淋巴结转移判断的准确性,对于提高食管癌患者的治疗水准和改善预后具有重要意义。目前还没有找到可以有效应用于食管癌术后复发和转移早期检测的血清标志物。如何提高食管癌早期诊断率、手术前淋巴结转移诊断准确性和有效监测治疗后复发及转移,尤其是寻找方便有效的血清诊断标志物,已经成为目前临床和基础研究的重要要方向。
蛋白质是生命活动的具体执行者和体现者,肿瘤的发展过程中往往有蛋白质的动态变化。蛋白质组学能够识别鉴定细胞、组织或机体的全部蛋白质,提供一组蛋白质的功能及其模式的信息,能够同时反映细胞内部的遗传特性和外界因素的影响的结果。因此,可以在蛋白质组的水平进行进一步探索,寻找用于肿瘤的术前诊断、分期和术后随访监测等方面特异、灵敏的标志物。利用差异蛋白质组学的研究方法对肿瘤和正常人群的差异表达蛋白进行定量、定性、表征分析并且筛选出肿瘤相关的蛋白标记物已成为目前研究的热点。随着蛋白质组学相关技术的迅速发展,临床血清蛋白质组学成为当今生命科学领域中极其活跃的学科,临床血清蛋白质组学从新的角度研究肿瘤,寻找肿瘤标志物,为肿瘤的早期诊断、预后和动态监测提供了重要依据。
表面增强激光解吸离子化飞行时间质谱(surface-enhanced laser desorption/ ionization time of flight mass spectrometry, SELDI-TOF-MS或SELDI)技术是一种将生物样品(如细胞液或体液)中的各种蛋白质通过特定的表面基团吸附于蛋白质芯片上,用激光脉冲辐射使芯片上的蛋白质解析形成荷电离子,这些不同质荷比(M/Z)的离子在真空电场中飞行的时间长短不同,据此绘制出质谱图,以获得各种蛋白质的分子量、丰度等信息。将正常人样本的图谱信息同某种疾病患者比较,就有望发现新的疾病相关蛋白质。SELDI-TOF-MS质谱技术已在许多肿瘤标志物研究中应用并取得成功。
应用蛋白质组学SELDI-TOF-MS技术对新疆不同民族血清蛋白质指纹图谱的检测结果提示汉族、哈萨克族、维吾尔族食管癌患者间的血清蛋白质指纹图谱存在着明显的差异。本研究采用SELDI-TOF-MS技术对新疆维吾尔族的血清蛋白质指纹图谱进行检测,结合临床以及病理学资料探讨血清目标蛋白质在新疆维吾尔族食管癌患者诊断和术前淋巴结转移判断当中的价值。分析SELDI-TOF-MS技术对食管癌患者手术治疗前后血清蛋白质表达差异检测结果,探讨可能的临床意义。
目的：本研究的目的是通过SELDI-TOF-MS质谱技术分析食管癌鳞癌患者和无癌健康者血清蛋白表达谱的改变以及手术前后的血清蛋白表达谱变化,筛选并建立维吾尔族食管鳞癌诊断和患者淋巴结转移诊断的血清标志物模型。寻找食管癌手术前后变化的血清标志物,进一步完善食管癌诊断、淋巴结转移及预后判断意义的食管癌蛋白表达谱系。这将有助于更深层次的理解食管癌基因学、蛋白组学改变以及加深对肿瘤发生机制的认识,为食管癌疾病早期诊断和和检测术后复发提供血清学的依据。本课题主要进行了三个方面的研究：1)新疆地区维吾尔族食管鳞癌患者与健康者血清差异表达蛋白的研究；2)新疆维吾尔族食管鳞癌淋巴结转移血清蛋白质指纹图谱研究；3)食管癌手术前后血清蛋白质组学变化研究。方法：采用弱阳离子交换蛋白芯片(CM10)和表面增强激光解吸离子化飞行时间质谱(SELDI)技术检测血清样本,应用ZUCI-Protein Chip Data Analyze System软件包分析所得到的数据。用支持向量机方法建立蛋白质指纹图诊断模型,用留—法交叉验证作为评估模型判别效果的方法。两组之间的蛋白质峰的比较采用Wilconxon秩和检验,P<0.05有统计学意义。1)检测分析了43例维吾尔族食管鳞癌患者和22例性别、年龄匹配的正常对照血清蛋白表达谱,建立新疆维吾尔族食管鳞癌诊断模型；2)检测分析了21例维吾尔族食管鳞癌有淋巴结转移、22例维吾尔族食管鳞癌无淋巴结转移的患者和22例维吾尔族正常对照的血清,筛选维吾尔族食管鳞癌淋巴结转移的血清标记物,建立维吾尔族食管癌淋巴结转移诊断模型。3)检测分析45例食管鳞癌患者的手术前和手术后血清蛋白表达谱,筛选手术前后发生变化的蛋白质标志物。结果：1)维吾尔族食管鳞癌组与正常对照血清蛋白M/Z峰值图谱明显不同。所得到差异性最大的10个蛋白中(P<0.05),有5个峰在食管癌组呈高表达,M/Z为4487.3973、11693.8038、9160.7745、5494.4509、15963.7368。5个峰呈低表达,M/Z为2763.4477、6648.88、8712.8596、6681.2584、8789.2461。建立了由7个蛋白(M/Z分别为：4487.3973、8712.8596、9160.7745、5494.4509、6681.25843、8789.2461、11693.8038)组成的诊断模型。采用十倍交叉留一法验证,该诊断模型的敏感度为86.05%(37/43),特异度为68.18%(15/22)；2)新疆维吾尔族食管鳞癌淋巴结阳性患者组,淋巴结阴性组和健康人血清的蛋白M/Z峰值图谱明显不同。筛选了6个蛋白质峰(M/Z4487.7591、5494.0576、7992.6041、5874.1964、5899.7251、8584.908)建立了维吾尔族食管癌淋巴结阴性患者诊断模型。用十倍交叉留一法验证,其敏感度为81.82%(18/22),特异度为86.36%(19/22)；建立了由6个蛋白质峰(M/Z 4487.6122、2763.5209、8713.1525、5494.5497、11693.2483、2750.9962)组成的维吾尔族食管鳞癌淋巴结阳性患者诊断模型。用十倍交叉留一法验证,其敏感度为80.95%(17/21),特异度为86.36%(19/22)；建立了由3个蛋白质峰(M/Z 3275.3129、9442.91、2046.0471)组成的维吾尔族食管鳞癌淋巴结转移诊断模型。用十倍交叉留一法验证,模型的敏感度为76.19%,特异度为77.27%；3)食管癌患者手术前后血清蛋白质指纹图谱存在明显差异,表达差异最大的10个蛋白质峰(P<0.05)中M/Z 8712.3909、8788.9114、6450.9811、8585.3391、6649.156、6899.7862手术后表达低于手术前,M/Z 11496.6914、16153.17、7993.1528、11418.0658手术后表达高于手术前。其中3个蛋白质峰(M/Z 8712.3909/8714.1856、8788.9114/8789.6786、6649.156/6649.9783)与此前筛选到的维吾尔族食管鳞癌患者与正常对照之间差异蛋白质峰相同。结论：1)表面增强激光解吸电离飞行时间质谱技术和生物信息学分析软件的联合应用是一种寻找食管癌鳞癌生物标志物的有效方法,构成的诊断模型可以准确灵敏的区分维吾尔族食管鳞癌和健康人；2)维吾尔族食管鳞癌淋巴结阳性患者,淋巴结阴性患者和健康对照组血清蛋白质指纹图谱明显不同。其中5个蛋白峰(M/Z为16081.0634、16152.0842、15962.2598、2019.8519、2044.3842)可能对判定病情预后有重要意义；3)新疆维吾尔族食管癌手术前后血清蛋白质组学变化研究筛选到的3个蛋白质峰(M/Z 8712.3909/8714.1856、8788.9114/8789.6786、6649.156/6649.9783)可能并非是肿瘤分泌的特异性标记物,有可能是与肿瘤患者体内原有的受到抑制免疫相关蛋白或因为进食困难较正常已经降低的营养状况相关指标,其分子特征有待进一步研究。
Esophageal carcinoma (EC) is one of the main digestive system malignant tumor. China is a country of high incidence of esophageal cancer and Esophageal squamous cell carcinoma (ESCC) accounts for about 80%of the total number. Epidemiological characteristics of esophageal cancer, the differences in ethnic distribution is one of its main features in addition to significant differences in geographical distribution. Esopha-geal cancer in Xinjiang has a significant regional and national aggregation, which suggest the incidence of esophageal cancer in Xinjiang be affected by the combined effect of environmental and genetic factors. Existing research for Uygur in Xinjiang only few studies on esophageal cancer, and insufficient information available. There is still a lack of early diagnosis of esophageal cancer. Most of the time of diagnosis of esophageal cancer patients are already in the late, their treatment is not so effective. Surgery is the main method of treatment of esophageal cancer. The leading death causes of patients with esophageal cancer after surgery are tumor recurrence and metastasis. Lymphatic metastasis (LM) is an important prognostic factor for esophageal cancer. Current problem is that we can not accurately determine the existence of LM before surgery. So it bring a certain blindness to surgery and treatment options. To improve TNM staging of patients prior to surgery, especially, to improve the accuracy of LM, show great significance for improving the treatment and improving the prognosis of patients with esophageal cancer. So far, there is no effective serum markers application found in diagnosis of esophageal cancer recurrence and metastasis in early stage. How to improve the early diagnosis of esophageal cancer and preoperative diagnostic accuracy of LM, and effective monitoring of recurrence and metastasis after treatment, especially look for convenient and effective diagnostic markers in serum, have become an important direction of clinical and basic research.
Protein is the actual implementation and embodiment of those life activities. The development of cancer often have protein dynamics. Proteomics can identify cells, tissues or whole body protein, which provides a set information of protein function and mode and also reflects the genetic characteristics and the results of the impacts of external factors on inside cells. So, looking for specific and sensitive marker for preoperative staging and postoperative follow-up monitoring calls for the further explora-tion for proteome. Using differential proteomics on the expression and quantitative differences between tumor and the normal or benign lesions, and characterization of selected tumor-associated protein markers has become a research hotspot. With the rapid development of proteomics-related technologies, clinical serum proteomics become very active in the field of life sciences disciplines. From a new angle, clinical serum proteomics studies and finds tumor markers, which provides an important basis for early cancer diagnosis, prognosis and dynamic monitoring.
A novel technology, surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) evared out such a new path to porteomics research on cancer. As high qunatities of data were obatined from proteomics fields, which traditonal mathematic and statistic methods can not analysis so much data efficiently. Proteins are captured by adsorption, partition, electrostatic interaction, or affinity chromatography on a solid-phase protein chip surface. The protein chip chromatographic surfaces in SELDI are uniquelydesigned to retain proteins from complex mixtures according to their specific properties. After adding a matrix solution, proteins can be ionized with a nitrogen laser and their molecular masses measured by TOF-MS. These different mass to charge ratio (M/Z) of ions in a vacuum electric field in the different lengths of time of flight, thus rendering the mass spectra to obtain a variety of protein molecular weight, abundance and other information. Compared with patients with a disease by their map information, the new disease-related proteins will be found. SELDI-TOF-MS mass spectrometry have been applied to the study biomarkers in many tumor and succeed.
Application of SELDI-TOF-MS technique on different nationalities for detection of serum protein fingerprint suggest that information of all health ethnic groups is different from patients with esophageal obviously. In this study, combined clinical and pathological data, SELDI-TOF-MS technology was used for explore the differences in serum proteins between patients with esophageal cancer and the healthy person and estimated the value of diagnosis and preoperative diagnosis of LM in Uygur patient with esophageal cancer in Xinjaing.
Objective:The following three aspects analyzed in this study ars to:1) Screen serum tumor biomakers and find diagnostic model of ESCC by SELDI-TOF-MS and ZUCI-Protein Chip Data Analyze System package (ZUCI-PCDAS) in Uygur in Xinjiang; 2) Screen serum tumor biomakers and find diagnostic model of LM of ESCC by SELDI-TOF-MS and PCDAS in Uygur in Xinjiang; 3) Screen serum tumor biomakers and analyze the perioperative dynamic variation of it by SELDI-TOF-MS in patients with ESCC. Methods:1) Serum samples from 42 ESCC Uygur's patients and 22 Uygur's healthy controls were analysed on weak cation exchange and hydrophobic surface protein chip (CM 10) using SELDI-TOF-MS technology in screen out the serum differentially expressed markers of ESCC; 2) Serum samples from 42 ESCC Uygur's patients,21 with and 22 without intrathoracic LM, were screened were detected on weak cation exchange (CM 10) protein chip using SELDI-TOF-MS technology. The obtained protein expression profiles data were devited into two groups named as diagnostic cast, and the results were analyzed using ZUCI-PDAS software in order to screen out serum differentially proteins. 3) Preoperative and postoperative serum samples from 45 patients were detected on weak cation exchangeand hydrophobic surface protein chip (CM10) using SELDI-TOF-MS technology. Also, serum samples of 64 patients and 63 health control the results were were detected. The result of these two groups were comparative analyzed to monitering dynamic variation of biomaker. Results:1) M/Zs were significantly different between ESCC patients and controls in Uygur (P<0.05). Among them, five proteins peaks (4487.3973、15963.7368、9160.7745、5494.4509、11693.8038) were high-expressed and five(2763.4477、8712.8596、6648.88、6681.2584、8789.2461) were low-expressed in ESCC group. According to cross validation, seven proteins composed and established diagnostic model. The sensitivity and specificity of the diagnostic model were 86.05%(37/43) and 68.18%(15/22); 2) M/Zs were significantly different between ESCC patients with and without LM in Uygur (P<0.05). According to cross validation, six proteins composed and established diagnostic model. The sensitivity and specificity of the diagnostic model were 76.19%(16/21) and 77.27%(17/22) respectively; 3) There was significantly difference of serum protein profiling between preoperative and postoperative patients. Three of protein peaks in preoperative sample, which was higher in health control than preoperative patients, was lower postoperatively. Conclusion:1) The combination of Surface-enhanced laser desorption ionization time of flight mass spectrometry and bioinformatics software analysis is a effective method searching for biomarkers of esophageal squamous cell carcinoma, constitutes sensitive diagnostic model can accurately distinguish esophageal squamous cell carcinoma and healthy Uygur. The established sensitive diagnostic model can accurately distinguish esophageal squamous cell carcinoma with healthy Uygur people; 2) The serum protein patterns were significantly different among uygur patients with positive lymph node detection, lymph node-negative patients and healthy controls,5 protein peaks (M/Z%16081.0634, 16152.0842,15962.2598,2019.8519,2044.3842) of which may be important for determining prognosis; 3) The three Screened protein peaks may not be specific markers secreted by tumor, may be suppressed immune related protein in the tumor patients, or relevant indicators of nutritional status because of swallowing difficulties compared with normal. Further study of its molecular characteristics is needed.
目前仍然缺乏食管癌的早期诊断方法,大部分食管癌患者确诊时已属中晚期,治疗的效果欠佳。手术治疗是食管癌治疗的主要方法,食管癌患者手术后死亡的主要原因是肿瘤复发和转移,肿瘤淋巴结转移是影响食管癌预后的重要因素之一。目前对手术前有无淋巴结转移判断存在不准确的问题,给手术和治疗方式选择带来了一定的盲目性。提高患者手术前TNM分期的准确率,特别是提高对淋巴结转移判断的准确性,对于提高食管癌患者的治疗水准和改善预后具有重要意义。目前还没有找到可以有效应用于食管癌术后复发和转移早期检测的血清标志物。如何提高食管癌早期诊断率、手术前淋巴结转移诊断准确性和有效监测治疗后复发及转移,尤其是寻找方便有效的血清诊断标志物,已经成为目前临床和基础研究的重要要方向。
蛋白质是生命活动的具体执行者和体现者,肿瘤的发展过程中往往有蛋白质的动态变化。蛋白质组学能够识别鉴定细胞、组织或机体的全部蛋白质,提供一组蛋白质的功能及其模式的信息,能够同时反映细胞内部的遗传特性和外界因素的影响的结果。因此,可以在蛋白质组的水平进行进一步探索,寻找用于肿瘤的术前诊断、分期和术后随访监测等方面特异、灵敏的标志物。利用差异蛋白质组学的研究方法对肿瘤和正常人群的差异表达蛋白进行定量、定性、表征分析并且筛选出肿瘤相关的蛋白标记物已成为目前研究的热点。随着蛋白质组学相关技术的迅速发展,临床血清蛋白质组学成为当今生命科学领域中极其活跃的学科,临床血清蛋白质组学从新的角度研究肿瘤,寻找肿瘤标志物,为肿瘤的早期诊断、预后和动态监测提供了重要依据。
表面增强激光解吸离子化飞行时间质谱(surface-enhanced laser desorption/ ionization time of flight mass spectrometry, SELDI-TOF-MS或SELDI)技术是一种将生物样品(如细胞液或体液)中的各种蛋白质通过特定的表面基团吸附于蛋白质芯片上,用激光脉冲辐射使芯片上的蛋白质解析形成荷电离子,这些不同质荷比(M/Z)的离子在真空电场中飞行的时间长短不同,据此绘制出质谱图,以获得各种蛋白质的分子量、丰度等信息。将正常人样本的图谱信息同某种疾病患者比较,就有望发现新的疾病相关蛋白质。SELDI-TOF-MS质谱技术已在许多肿瘤标志物研究中应用并取得成功。
应用蛋白质组学SELDI-TOF-MS技术对新疆不同民族血清蛋白质指纹图谱的检测结果提示汉族、哈萨克族、维吾尔族食管癌患者间的血清蛋白质指纹图谱存在着明显的差异。本研究采用SELDI-TOF-MS技术对新疆维吾尔族的血清蛋白质指纹图谱进行检测,结合临床以及病理学资料探讨血清目标蛋白质在新疆维吾尔族食管癌患者诊断和术前淋巴结转移判断当中的价值。分析SELDI-TOF-MS技术对食管癌患者手术治疗前后血清蛋白质表达差异检测结果,探讨可能的临床意义。
目的：本研究的目的是通过SELDI-TOF-MS质谱技术分析食管癌鳞癌患者和无癌健康者血清蛋白表达谱的改变以及手术前后的血清蛋白表达谱变化,筛选并建立维吾尔族食管鳞癌诊断和患者淋巴结转移诊断的血清标志物模型。寻找食管癌手术前后变化的血清标志物,进一步完善食管癌诊断、淋巴结转移及预后判断意义的食管癌蛋白表达谱系。这将有助于更深层次的理解食管癌基因学、蛋白组学改变以及加深对肿瘤发生机制的认识,为食管癌疾病早期诊断和和检测术后复发提供血清学的依据。本课题主要进行了三个方面的研究：1)新疆地区维吾尔族食管鳞癌患者与健康者血清差异表达蛋白的研究；2)新疆维吾尔族食管鳞癌淋巴结转移血清蛋白质指纹图谱研究；3)食管癌手术前后血清蛋白质组学变化研究。方法：采用弱阳离子交换蛋白芯片(CM10)和表面增强激光解吸离子化飞行时间质谱(SELDI)技术检测血清样本,应用ZUCI-Protein Chip Data Analyze System软件包分析所得到的数据。用支持向量机方法建立蛋白质指纹图诊断模型,用留—法交叉验证作为评估模型判别效果的方法。两组之间的蛋白质峰的比较采用Wilconxon秩和检验,P<0.05有统计学意义。1)检测分析了43例维吾尔族食管鳞癌患者和22例性别、年龄匹配的正常对照血清蛋白表达谱,建立新疆维吾尔族食管鳞癌诊断模型；2)检测分析了21例维吾尔族食管鳞癌有淋巴结转移、22例维吾尔族食管鳞癌无淋巴结转移的患者和22例维吾尔族正常对照的血清,筛选维吾尔族食管鳞癌淋巴结转移的血清标记物,建立维吾尔族食管癌淋巴结转移诊断模型。3)检测分析45例食管鳞癌患者的手术前和手术后血清蛋白表达谱,筛选手术前后发生变化的蛋白质标志物。结果：1)维吾尔族食管鳞癌组与正常对照血清蛋白M/Z峰值图谱明显不同。所得到差异性最大的10个蛋白中(P<0.05),有5个峰在食管癌组呈高表达,M/Z为4487.3973、11693.8038、9160.7745、5494.4509、15963.7368。5个峰呈低表达,M/Z为2763.4477、6648.88、8712.8596、6681.2584、8789.2461。建立了由7个蛋白(M/Z分别为：4487.3973、8712.8596、9160.7745、5494.4509、6681.25843、8789.2461、11693.8038)组成的诊断模型。采用十倍交叉留一法验证,该诊断模型的敏感度为86.05%(37/43),特异度为68.18%(15/22)；2)新疆维吾尔族食管鳞癌淋巴结阳性患者组,淋巴结阴性组和健康人血清的蛋白M/Z峰值图谱明显不同。筛选了6个蛋白质峰(M/Z4487.7591、5494.0576、7992.6041、5874.1964、5899.7251、8584.908)建立了维吾尔族食管癌淋巴结阴性患者诊断模型。用十倍交叉留一法验证,其敏感度为81.82%(18/22),特异度为86.36%(19/22)；建立了由6个蛋白质峰(M/Z 4487.6122、2763.5209、8713.1525、5494.5497、11693.2483、2750.9962)组成的维吾尔族食管鳞癌淋巴结阳性患者诊断模型。用十倍交叉留一法验证,其敏感度为80.95%(17/21),特异度为86.36%(19/22)；建立了由3个蛋白质峰(M/Z 3275.3129、9442.91、2046.0471)组成的维吾尔族食管鳞癌淋巴结转移诊断模型。用十倍交叉留一法验证,模型的敏感度为76.19%,特异度为77.27%；3)食管癌患者手术前后血清蛋白质指纹图谱存在明显差异,表达差异最大的10个蛋白质峰(P<0.05)中M/Z 8712.3909、8788.9114、6450.9811、8585.3391、6649.156、6899.7862手术后表达低于手术前,M/Z 11496.6914、16153.17、7993.1528、11418.0658手术后表达高于手术前。其中3个蛋白质峰(M/Z 8712.3909/8714.1856、8788.9114/8789.6786、6649.156/6649.9783)与此前筛选到的维吾尔族食管鳞癌患者与正常对照之间差异蛋白质峰相同。结论：1)表面增强激光解吸电离飞行时间质谱技术和生物信息学分析软件的联合应用是一种寻找食管癌鳞癌生物标志物的有效方法,构成的诊断模型可以准确灵敏的区分维吾尔族食管鳞癌和健康人；2)维吾尔族食管鳞癌淋巴结阳性患者,淋巴结阴性患者和健康对照组血清蛋白质指纹图谱明显不同。其中5个蛋白峰(M/Z为16081.0634、16152.0842、15962.2598、2019.8519、2044.3842)可能对判定病情预后有重要意义；3)新疆维吾尔族食管癌手术前后血清蛋白质组学变化研究筛选到的3个蛋白质峰(M/Z 8712.3909/8714.1856、8788.9114/8789.6786、6649.156/6649.9783)可能并非是肿瘤分泌的特异性标记物,有可能是与肿瘤患者体内原有的受到抑制免疫相关蛋白或因为进食困难较正常已经降低的营养状况相关指标,其分子特征有待进一步研究。
Esophageal carcinoma (EC) is one of the main digestive system malignant tumor. China is a country of high incidence of esophageal cancer and Esophageal squamous cell carcinoma (ESCC) accounts for about 80%of the total number. Epidemiological characteristics of esophageal cancer, the differences in ethnic distribution is one of its main features in addition to significant differences in geographical distribution. Esopha-geal cancer in Xinjiang has a significant regional and national aggregation, which suggest the incidence of esophageal cancer in Xinjiang be affected by the combined effect of environmental and genetic factors. Existing research for Uygur in Xinjiang only few studies on esophageal cancer, and insufficient information available. There is still a lack of early diagnosis of esophageal cancer. Most of the time of diagnosis of esophageal cancer patients are already in the late, their treatment is not so effective. Surgery is the main method of treatment of esophageal cancer. The leading death causes of patients with esophageal cancer after surgery are tumor recurrence and metastasis. Lymphatic metastasis (LM) is an important prognostic factor for esophageal cancer. Current problem is that we can not accurately determine the existence of LM before surgery. So it bring a certain blindness to surgery and treatment options. To improve TNM staging of patients prior to surgery, especially, to improve the accuracy of LM, show great significance for improving the treatment and improving the prognosis of patients with esophageal cancer. So far, there is no effective serum markers application found in diagnosis of esophageal cancer recurrence and metastasis in early stage. How to improve the early diagnosis of esophageal cancer and preoperative diagnostic accuracy of LM, and effective monitoring of recurrence and metastasis after treatment, especially look for convenient and effective diagnostic markers in serum, have become an important direction of clinical and basic research.
Protein is the actual implementation and embodiment of those life activities. The development of cancer often have protein dynamics. Proteomics can identify cells, tissues or whole body protein, which provides a set information of protein function and mode and also reflects the genetic characteristics and the results of the impacts of external factors on inside cells. So, looking for specific and sensitive marker for preoperative staging and postoperative follow-up monitoring calls for the further explora-tion for proteome. Using differential proteomics on the expression and quantitative differences between tumor and the normal or benign lesions, and characterization of selected tumor-associated protein markers has become a research hotspot. With the rapid development of proteomics-related technologies, clinical serum proteomics become very active in the field of life sciences disciplines. From a new angle, clinical serum proteomics studies and finds tumor markers, which provides an important basis for early cancer diagnosis, prognosis and dynamic monitoring.
A novel technology, surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) evared out such a new path to porteomics research on cancer. As high qunatities of data were obatined from proteomics fields, which traditonal mathematic and statistic methods can not analysis so much data efficiently. Proteins are captured by adsorption, partition, electrostatic interaction, or affinity chromatography on a solid-phase protein chip surface. The protein chip chromatographic surfaces in SELDI are uniquelydesigned to retain proteins from complex mixtures according to their specific properties. After adding a matrix solution, proteins can be ionized with a nitrogen laser and their molecular masses measured by TOF-MS. These different mass to charge ratio (M/Z) of ions in a vacuum electric field in the different lengths of time of flight, thus rendering the mass spectra to obtain a variety of protein molecular weight, abundance and other information. Compared with patients with a disease by their map information, the new disease-related proteins will be found. SELDI-TOF-MS mass spectrometry have been applied to the study biomarkers in many tumor and succeed.
Application of SELDI-TOF-MS technique on different nationalities for detection of serum protein fingerprint suggest that information of all health ethnic groups is different from patients with esophageal obviously. In this study, combined clinical and pathological data, SELDI-TOF-MS technology was used for explore the differences in serum proteins between patients with esophageal cancer and the healthy person and estimated the value of diagnosis and preoperative diagnosis of LM in Uygur patient with esophageal cancer in Xinjaing.
Objective:The following three aspects analyzed in this study ars to:1) Screen serum tumor biomakers and find diagnostic model of ESCC by SELDI-TOF-MS and ZUCI-Protein Chip Data Analyze System package (ZUCI-PCDAS) in Uygur in Xinjiang; 2) Screen serum tumor biomakers and find diagnostic model of LM of ESCC by SELDI-TOF-MS and PCDAS in Uygur in Xinjiang; 3) Screen serum tumor biomakers and analyze the perioperative dynamic variation of it by SELDI-TOF-MS in patients with ESCC. Methods:1) Serum samples from 42 ESCC Uygur's patients and 22 Uygur's healthy controls were analysed on weak cation exchange and hydrophobic surface protein chip (CM 10) using SELDI-TOF-MS technology in screen out the serum differentially expressed markers of ESCC; 2) Serum samples from 42 ESCC Uygur's patients,21 with and 22 without intrathoracic LM, were screened were detected on weak cation exchange (CM 10) protein chip using SELDI-TOF-MS technology. The obtained protein expression profiles data were devited into two groups named as diagnostic cast, and the results were analyzed using ZUCI-PDAS software in order to screen out serum differentially proteins. 3) Preoperative and postoperative serum samples from 45 patients were detected on weak cation exchangeand hydrophobic surface protein chip (CM10) using SELDI-TOF-MS technology. Also, serum samples of 64 patients and 63 health control the results were were detected. The result of these two groups were comparative analyzed to monitering dynamic variation of biomaker. Results:1) M/Zs were significantly different between ESCC patients and controls in Uygur (P<0.05). Among them, five proteins peaks (4487.3973、15963.7368、9160.7745、5494.4509、11693.8038) were high-expressed and five(2763.4477、8712.8596、6648.88、6681.2584、8789.2461) were low-expressed in ESCC group. According to cross validation, seven proteins composed and established diagnostic model. The sensitivity and specificity of the diagnostic model were 86.05%(37/43) and 68.18%(15/22); 2) M/Zs were significantly different between ESCC patients with and without LM in Uygur (P<0.05). According to cross validation, six proteins composed and established diagnostic model. The sensitivity and specificity of the diagnostic model were 76.19%(16/21) and 77.27%(17/22) respectively; 3) There was significantly difference of serum protein profiling between preoperative and postoperative patients. Three of protein peaks in preoperative sample, which was higher in health control than preoperative patients, was lower postoperatively. Conclusion:1) The combination of Surface-enhanced laser desorption ionization time of flight mass spectrometry and bioinformatics software analysis is a effective method searching for biomarkers of esophageal squamous cell carcinoma, constitutes sensitive diagnostic model can accurately distinguish esophageal squamous cell carcinoma and healthy Uygur. The established sensitive diagnostic model can accurately distinguish esophageal squamous cell carcinoma with healthy Uygur people; 2) The serum protein patterns were significantly different among uygur patients with positive lymph node detection, lymph node-negative patients and healthy controls,5 protein peaks (M/Z%16081.0634, 16152.0842,15962.2598,2019.8519,2044.3842) of which may be important for determining prognosis; 3) The three Screened protein peaks may not be specific markers secreted by tumor, may be suppressed immune related protein in the tumor patients, or relevant indicators of nutritional status because of swallowing difficulties compared with normal. Further study of its molecular characteristics is needed.
引文
[1]Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2002[J]. CA Cancer J Clin,2005,55(2):74-108.
[2]Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden:Globocan 2000[J]. Int J Cancer,2001,94(2):153-156.
[3]Layke JC, Lopez PP. EsoPhageal cancer:a review and update[J]. Am Fam Physician,2006,73(12):2187-2194.
[4]汤钊猷.现代肿瘤学[M].2版.上海：复旦大学出版社,2000：20-25.
[5]Holmes RS, TL Vaughan. Epidemioloy and pathogenesis of esophageal cancer[J]. Semin Radiat Oncol,2007,17(1):2-9.
[6]Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007[J]. CA Cancer J Clin,2007, 57(1):43-66.
[7]Valberg PA, Long CM, Sax SN, et al. Integrating studies on carcinogenic risk of carbon black:epidemiology, animalexposures and mechanism of action[J]. J Occup Environ Med,2006.48(12):1291-1307.
[8]邹小农.食管癌流行病学[J].中华肿瘤防治杂志,2006,13(18)：181-184.
[9]林东昕.中国食管癌分子流行病学研究[J].中华流行病学杂志2003,24(10)：939-943.
[10]周福有,王立东.食管癌早期诊断方法的哲学思考[J].医学与哲学(临床决策论坛版).2008,10(29)：69-72.
[11]侯浚.食管癌的防治流行病学[J].食管外科,2007,6(1)：16-21.
[12]李连弟,鲁风珠,牧人,等.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1)：3-9.
[13]陈伟三,杨合麟.广东南澳县1987-1992年食管癌流行病学特点[J].癌症,1996,15(4)：274-276.
[14]Wang LD, Zheng S. The mechanism of esophageal and gastric cardia carcinogenesis from the subjects at high-incidence area for esophageal cancer in henna[J]. Zhengzhou daxue xuebao,2002,37(6):717-729.
[15]Rose EF. Cancer of oesophagus [J]. S Afr J Hosp Med,1978,4(2):110.
[16]Yang PC, Davis s.Incidence of cancer of the esophagus in the U. S. by histolgic type[J]. Cancer,1988,61(3):612-617.
[17]Blot WJ, Fraumeni JF.Trends in esophagus cancer mortality among U. S. blacks and whites[J]. Am J Public Health,1987,77(3):296-298.
[18]杨文献.食管癌的流行病学特征[M].见：杜百廉,食管癌,北京：中国科学技术出版社,1994,34-35.
[19]Zhang YM. Distribution of esophageal cancer in xinjiang[J]. Xinjiang yixueyuan xuebao,1988,11 (2):139-144.
[20]王秀梅,杰恩斯,马彦清.新疆哈萨克族食管癌危险因素病例对照研究[J].中国公共卫生.2007,23(6)：737-738.
[21]平育敏,张以德,杜喜群,等.食管癌和责门癌20000例外科治疗经验[J].见：中国首届国际食管癌学术会议暨第七届全国食管癌学术会议论文集.2005：161-171.
[22]邵令方,高崇人,许金良,等.管癌和贲门癌外科治疗15707例总结----附河南省食管癌的防治研究概况[J].见：中国首届国际食管癌学术会议暨第七届全国食管癌学术会议论文集.2005：40-45.
[23]Tachibana M, Kinugasa S, Shibakita M, et al. Review;Surgical treatment of superficial esophageal cancer[J]. Langenbeck Arch Surg,2006,391(4):304-321.
[24]邵令方,高宗人,李章才,等.204例早期食管癌和责门癌切除治疗的远期结果[J].中华外科杂志,1993,31(3)：131-133.
[25]Wang GQ, Jiao GQ, Cheng FB, et al. long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening[J]. Ann Thorac Surg,2004,77(5):1740-1744.
[26]张合林,平育敏,杜喜群,等.应用Cox模型分析影响食管癌切除术后预后因素[J].中华肿瘤杂志,1999,21(1)：32-34.
[27]张合林,平育敏,白世祥,等.食管鳞癌淋巴结转移对预后影响的分析[J].中国肿瘤临床,2001,28(5)：340-343.
[28]李国仁,戴建华.食管癌淋巴结转移研究状况及其治疗策略.中国肿瘤,2007,16(1)：915-919.
[29]刘巍,陈勇.食管癌淋巴结转移相关研究[J].中国肿瘤临床,2008,35(21)：1253-1260.
[30]Hsu CP, Chen CY, Hsia JY, et al. Prediction of prognosis by theextent of lymph node involvement in squamous cell carcinoma of the thoracic esophagus [J]. Eur J Cardiothorac Surg,2001,19(1):10-13.
[31]Pearson FG, Cooper JD, Deslauriers J, et al. Esophageal Surgery [M]. Heal Science Asia, Elsevier Science,2002,714.
[32]Akiyama H, Tsurumaru M, Udagawa H, et al. Radical lymph node dissection for cancer of the thoracic esophagus[J]. Ann Surg,1994,220(3):364-372.
[33]Nakajima Y, Nagai K, Miyoke S, etal. Evaluation of metastasis of esophageal squamous cell carcinoma invading the submucosal layer[J]. Jpn J Cancer Res, 2002,93(3):305-312.
[34]Araki K, Ohno S, Egashira A. et al. Pathologic features of superfecial esophageal squmous cell carcinoma with lymphnode and distal metastasis[J]. Cancer,2002, 94(2):570-575.
[35]Kodama M, Kakagama T. Treatment of superficial cancer of the thoracic esophagus:A summary of responses to a questionnaire on superficial cancer of the esophagus in Japan[J]. Surgery,1998,123(4):432-439.
[36]许运龙,郭昭扬.胸部食管癌转移淋巴结数与预后的临床研究[J].中华肿瘤杂志,2000,22(3)：244-246.
[37]Shimada H, Okazumi S, Matsubara H, et al. Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymphnode dissection[J]. World J Surg,2006, 30(8):1441-1449.
[38]Nakamura T, Ide H, Eguchi R, et al. Clinical implications of lymph node micrometastasis in patients with histologically node-negative(pNO)esophageal carcinoma[J]. J Surg Oncol,2002,79(4):224-229.
[39]Sato F, Shimada Y, Li Z, et al. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma [J]. Br J Surg,2001, 88(3):426-432.
[40]Igaki H, Tachimori Y, Kato H. Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection[J]. Ann Surg,2004, 239(4):483-490.
[41]Tabira Y, Kitamura N, Yoshioka M, et al. Significance of three-field lymphadenectomy for carcinoma of the thoracic esophagus based on depth of tumor infiltration, lymph nodal involvement and survival rate[J]. J Cardiovasc Surg(Torino),1999,40(5) 737-740.
[42]Law S, Wong J. Two-field dissection is enough for esophageal cancer[J]. Dis Esophagus,2001,14(2):98-103.
[43]Nozoe T, Kakeji Y, Baba H, et al. Two-field lymph-node dissection may be enough to treat patients with submucosal squamous cell carcinoma of the thoracic esophagus[J]. Dis Esophagus,2005,18(4):226-229.
[44]王洲,刘相燕,刘凡英,等.N0期食管癌术后早期复发与淋巴结微转移的相关性研究[J].中华外科杂志,2004,42(2)：68-71.
[45]Shiozkai H, Doki Y, Kawnaishi K, et al. Clinical application of malignancy potential grading as a prognostic acftor of human esophageal cancers[J]. Surgery, 2000,127(5):552-561.
[46]Stoop AA, Jespers L, Lasters T, et al. High-denisty mutagenesis by combined DNA shuffling and phage display to assign essential amino acid in Protein—Protein interaction:application to study structure function of plas minogen activation inhibitor. [J]. MolBiol,2000,301(5):1135-1147.
[47]Broemknna JG, St Nottberg H, Glodny B, et al. CYFRA21-1 Serum analysis in patients with esophageal cancer[J]. Clin Cancer Res,2000,6(11):4249-4252.
[48]Ychou M, Khemissa-AkouzF, Krmaar A, et al. A comparison of seurm Cyfra 21-1 and SCC AG in the diagnosis of squmaous cell esophageal carcinoma[J]. Bull Cancer,2001,88(10):1023-1027.
[49]Kwauguchi H, Ohno S, Miyazkai M, et al. CYFRA21-1 detection in patients with esophageal squmaous cell carcinoma:clinical utiliy for detection of recurrences[J]. Cancer,2000,89(7):1413-1417.
[50]Ikeguchi M, Oka S, Gomyo Y, et al. Combined analysis of p53and retinoblastoma protein exepressions in esophageal cancer[J]. Ann Thorac Surg,2000,70(3):913-917.
[51]Banks RE, Dunn MJ, Hochstrasser DF, et al. Proteomics:new perspectives, new biomedical opportunities. Lancet,2000,356(9243):1749-1756.
[52]Arrell DK, Neverova I, Van Eyk JE. CardiovascularProteomics:evolution and potential[J]. CircRes,2001,88(8):763-773.
[53]Wasinger VC, Cordwell SJ, Cerpa-Poljak A, et al. Progress with gene-product mapping of the Mollicutes:Mycoplasma genitalium [J]. Electrophoresis,1995, 16(7):1090-1094
[54]Li J, ZhangZ, Rosenzweig J, eta.1 Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer[J]. Clin-Chem,2002, 48(8):1296-1304.
[55]QiY, Chiu JF, Wang L, et al. Comparative proteomic analysis of esophageal squamous cell carcinoma [J]. Proteomics,2005,5(11):2960.
[56]Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor:a heat activated ion channel in the pain pathway[J]. Nature,1997,389(6653):816.
[57]Hoffinann P, Ji H, Moritz RL, et al. Continuous free-flow electorphoersis of cytosolic proteins from the human colon cacrinoma cell line LIM1215:a non two-dimensional gel electrophoresis-based proteome annalysis strategy [J]. Proteomics,2002,1(7):807-818.
[58]Hutchens TW, Yip TT. New desoprtion srtategies of the mass specrtomic analysis of macromolecules[J]. Rpaid Commun Mass specrtom,1993,7(7):576-580.
[59]Weinberger SR, Morris TS, Pawlak M. Recent trends in protein biochip technology [J]. Pharmacogenomics,2000,1(4):395-416.
[60]Vlahou A, Laronga C, Wilson L, et al. A novel approch toward development of a rapid blood test for breast cancer[J]. Clin Breast Cnacer.2003,4(3):203-209.
[61]von Eggeling F, Davies H, Lomas L, et al. Tissue-specific microdissection coupled with proetinchip array technologies:applications in cancer research[J]. Bio Techniques,2000,29(5):1066-1070.
[62]Pwaeletz CP, Trock B, Pennanen M, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF:potential for new biomakrers to aid in the diagnosis of breast cancer[J]. Dis Markers,2001,17(4):301-307.
[63]Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis associated protein I as a biomarker for pnacreatic ductal adenocarcinoma by protein biochip technology [J]. Cancer Res,2002,62(6):1865-1575.
[64]Vlahou A, Sehellhammer PF, Mendrinos S, et al. Development of a noval proteomics approach for the detection of transitional cell carcinoma of bladder in urine[J]. Am J Pathol,2001,158(4):1491-1502.
[65]Mannes AJ, Martin BM, Yang HY, et al. Cystatin C as a eerebrospinal fluid biomaker for pain in humans[J]. Pain,2003,102(3):251-256.
[66]Beher D, Wrigley JD, Owens AP, et al. Generation of C-terminally truncated amayloid-beta peptides is dependent on gamma-secretase activity[J]. J Neurochem, 2002,82(3):563-575.
[67]Clarke W, Silverman BC, Zhang S, et al. Characterization of renal allograft rejection by urinary proteomic analysis[J]. Ann Surg,2003,237(5):660-664.
[68]Qu Y, Adxna BL, Yasui Y, et al. Boosted decision tree analysis of surafce-enhanced laser desorption/ionization masss spectral serum profile discriminates Prostate cancer from noncancer patients[J]. Clin Chem,2002,48(10):1835-1843.
[69]Wright Jr GL, Cazares LH, Leung SM, et al. Proteinchip(R) surafce enhanced laser desorption/ionization(SELDI)mass spectrometry:a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures[J]. Prostate Cancer Prostatic Dis,1999,2(6):264-276.
[70]Adma BL, Qu Y, Dvais JW, et al. Serum protein fingerprinting coupled with a patter-matching algorithm distinguishes prostate cancer from benign prostatehyperplasia and and healhty men[J]. Cancer Res,2002,62(13):3609-3614.
[71]LI J, Zhnag Z, Rosenzweig J, et al. Proteomic and informatics approaches for identification of serum biomarkers to detect breast cancer[J]. Clinical Chemistry, 2002,48(8):1296-1304.
[72]Jones MB, Krutzsch H, Shu H, et al. Proetomic analysis and identification of new biomarkers and therapeutic targets for overian cancer[J]. Proteomics,2002, 2(1):76-84.
[73]Rai AJ, Zhnag Z, Rosenzweig J, et al. Proteomic apporaches to tumor marker discovery[J]. Arch Pathol Lab Med,2002,126(12):1518-1526.
[74]Xiao XY, Tang Y, Wei XP, etal. A preliminary analysis of non-small cell lung cancer biomarkers in serum[J]. Biomed Environ Sci,2003,16(2):140-148.
[75]Zhao X, Mao Y, Zhang L, et al. Porgram/Proceedings Supplement of American Association for Cancer Research.2002:79.
[76]Chen YD, Zheng S, Yu JK, et al. Artificial neural network analysis of surface-enhanced laser desoprtion/ionization mass spectra of seurm protein fingerprinting distiguishes colorectal cancer from healthy population. Clinical Cancer Res,2004,10(24):8380-8385.
[77]Wang YY, Zhang Z, White N, et al. Detection of cancer biomarkers by SELDI proteomics technology from serum in colorectal carcinoma[J]. Proceedings of the AACR, Toronio, Ontario, Canada,2003;44(3):6320.
[78]Cazares L, Wdasworth JT, Somers KD, et al. Serum protein expression profiles identify head and neck cancer [J]. Proceedings of the AACR, Toronio, Ontario, Canada,2003; 44(3):1521.
[79]White CN, Chan DW, Zhang Z. Bioinformatics strategies for Proteomic Profiling[J]. Clin Biochem,2004,37(3):636-641.
[80]Boguski MS, Meintosh MW. Biomedical informatics for Proteomics [J]. Nature, 2003,422(6928):233-237.
[81]Ball G, Mian S, Holding F, et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumor and rapid identification of potential biomarkers[J]. Bioinformatics,2002,18(3): 395-404.
[82]Narayanan A, Keedwell EC, Olsson B. Artificial intelligence techniques bioinformatics[J]. Appll Bioinformatics,2002,1 (4):191-192.
[83]余捷凯,郑树,唐勇,等.血清蛋白质谱与人工神经网络模型诊断卵巢癌的应用性研究[J].中华检验医学杂志,2005,25(5)：480-482.
[84]雷英杰,张善文,李续武,等MATLAB遗传算法工具箱及应用[M].西安：西安电子科技大学出版社,2005：11-16.
[85]张昌明,李德生,张海平,等.食管癌血清差异蛋白的研究[J].中华消化外科杂志,2010,9(6)：444-446.
[86]张昌明,张海平,张琼,等.新疆哈萨克族患者血清蛋白质指纹图谱分析.中华医学杂志,2011,91(3)：171-174.
[87]刘建,郑树,余捷凯,等.胶质瘤脑脊液蛋白指纹图质谱仪分析及其在临床诊断中的应用[J].中华神经外科,2004,20(5)：362-366.
[88]Chen G, Tarek TG, Huang CC, et al. Proteomicanalysis of lung adenocarcinoma: Identification of ahighly expressed set of proteins in tumors [J]. Clin Cancer Res, 2002,8(7):2298-2305.
[89]Qu YS, Adam BL, Yutaka Y, et al. Boosted Decision Tree analysis of Surface-enhanced Laser Desorption/Ionization mass spectral serum profiles discriminates prostate cancer from noncancer Patients[J]. Clin Chem,2002,48(10):1835-1843.
[90]陈益定,郑树,余捷凯,等.血清蛋白质质谱模型在大肠癌诊断中的应用[J].中华肿瘤杂志,2004,26(7)：381-383.
[91]王庆荣,张琼,张朝霞,等.新疆地区汉族、维吾尔族及哈萨克族食管癌血清蛋白质指纹图谱研究[J].临床检验杂志,2009,27(6)：195-197.
[92]Chan A, Wong A. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma? Int J Radiat Oncol Biol Phys,1999,45(2):265-270.
[93]安丰山,黄金球,谢映涛,等.食管癌新辅助放化疗的前瞻性临床研究[J].中华肿瘤杂志,2003,25(4)：376-379.
[94]Yang H, Berner A, Mei Q, et al. Cytologic screening for esophageal cancer in a high-risk population in anuang county[J]. China. Acta Cytol,2002,46(3);445-52.
[95]Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma[J]. Cancer,2002,94(4):921-928.
[96]宁国庆,袁宪顺,吕守臣,等.螺旋CT增强扫描对食管癌淋巴结转移的诊断价值[J].医学影像学杂志,2007,17(2)：148-151.
[97]Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer,100 consecutive position emission tomography scans[J]. Ann Thorac Surg,1999,68(4):1133-1136.
[98]Yoon YC, Eee KS, Shim YM, et al. Metastasis to regional lymph nodes in patients with esophageal squarnous cell carcinoma:CT versus FDG PET for presurgical detection prospective study[J]. Radiology,2003,227(3):764.-770.
[99]van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer.a meta-analysis[J]. BR J Cancer,2008,98(3):547-557.
[100]JinY, Zhang W, Liu B. et al. Abnomal expression of p53, Ki67 and iNOS in human esophageal carcinoma in situ and pre-malignant lesions P53[J]. Chinese J Oncology,2001,23(2):129-231.
[101]Zhang W, Rashid A, Wu H, et al. Dieffrential expression of retinoic acid receptors and p53protein in normal, premalignant, and malingnat esophageal tissues[J]. J Cancer Res Clin Oncol,2001,127(4):237-242.
[102]Shimada H, Takeda A, Arima M, et al. Serun p53antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma[J]. Cnacer,2000, 89(8):1677-1683.
[103]Brockmann JG, St Nottberg H, Glodny B, et al. CYFRA2-1 Serum analysis in patients with esophageal cancer[J]. Clin Cancer Res,2000,6(11):4249-4252.
[104]Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA21-1 determination in patients with esophageal squmaous cell carcinoma:clinical utility for detection of recurrences [J]. Cancer,2000,89(7):1413-1417.
[105]Yang EC, Guo J, Diehl G, et al. Protein expression profiling of endometrial malingnacies reveals a new tumor marker:chaperonin1O[J]. J Porteome Res,2004, 3(3):636-643.
[106]施民新,刘茶珍,刘继斌,等.应用SELDI-TOF-MS技术分析南通地区食管癌血清差异表达蛋白[J].现代肿瘤医学,2006,14(11)：1360-1361.
[107]刘茶珍,朱佩云,施民新,等.应用IMAC3蛋白芯片分析食管鳞癌患者血清蛋白质谱的变化[J].癌症,2008,27(3)：272-278.
[108]Xu SY, Liu Z, Ma WJ, et al. New potential biomarkers in the diagnosis of esophageal squamous cell carcinoma[J]. Biomarkers,2009,14(5):340-346.
[109]Albethsen J, Bogebo R, Olsen J, et al. Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum[J]. Clin Chem Lab Med,2006,44(10):1243-1252.
[110]Malle E. Sodin Semrl S,Kovacevic A, et a.l Serum amyloid A:an acute-phase protein involved in tumour pathogenesis[J].Cell Mol Life Sc,i 2009,66(1):9-26.
[111]Urieli-Shoval S,Shubinsky G,Linke RP,et al. Adhesion of human platelets to serum amyloid A[J].Blood,2002,99(4):1224-1229.
[112]Wood SL, Rogers M, Cairns DA,et al. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. British Journal of Cancer[J], 2010,103(1),101-111
[113]Michaeli A,Finci-Yeheskel Z,Dishon S,et al.Serum amyloid A enhances plasm inogenactivation:implication for a role in colon cancer[J].Biochem Biophys Res Commun,2008,368(2):368-373.
[114]Freeman MR, Solomon KR. Cholesterol and Prostate cancer[J]. J Cell Biochem, 2004,91(1):54-69.
[115]Myers RB, Oelschlager DK, Weiss HL, et al. Fatty acid synthase:a nearly molecular maker of progression of prostastic adenomalignant to androgen independence[J]. J Urol,2001,165(3):1027-1032.
[116]Trougakos IP, GonosES. Clusterin/Apolipoprotein J in human aging and cancer[J]. Int J Biochem Cell Biol,2002,34(11):1430-1448.
[117]Malik G, Ward MD, Gupta SK, et al. Serum Levels of an isoform of apolipoprotein A-11 as a potential marker for prostatc cancer[J]. ClinCancer Res,2005, 11(3):1073-1085.
[118]Funahashi T, Yokoyama S, Yamamoto A. Association of apolipoprotein with the low-density lipoprotein receptor:demonstration particles[J]. J Biochem,1989, 105(4):582-587.
[119]Park W.-R., Nakamura Y. p53CSV, a novel p53-inducible gene involved in the p53-dependent cell-survival pathway[J]. Cancer Res.2005,65(4):1197-1206.
[120]Oda K, Arakawa H, Tanaka T, et al. p53AIPl, a potential media-tor of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53[J]. Cell, 2000,102(6):849-862.
[121]Seam N, Gonzales D A, Kern S J, et al. Quality control of serum albumin depletion forproteomic analysis[J]. Clin Chem,2007,53(11):1915-1920.
[122]Rollin D, Whistler T, Vernon SD. Laboratory methods to improve SELDI peak detection and quantitation[J]. Proteomc Sci,2007,5:9-14.
[123]黄国俊.外科手术在胸部恶性肿瘤治疗中的地位[J].中华外科杂志,2003,41(6)：401-403.
[124]Robinson JC, Kerjan P, Mirands M. Meromolecular assemblage of aminoacy tRNA synthetasses:quantitative analysis of protein-protein interactions and mechanism of complex assembly[J]. J Mol Biol,2000,304(5):983-994.
[125]Stoop AA, Jespers L, Lasters T, et al. High-denisty mutagenesis by combined DNA shuffling and Phage display to assign essential amino acid in protein-protein interaction:application to study structure function of plas minogen activation inhibitor[J]. Mol Biol,2000,301(5):1135-1147.
[126]Lu ZM, Zhang H, Wang MH, et al. Lymphatic metastasis intensity of and lymphadenectomy for thoracic esophageal squamous cell carcinoma[J]. AiZheng, 2006,25(5):604-608.
[127]Wu LF, Wang BZ, Feng JL, et al. Preoperative TN staging of esophageal cancer:comparison of miniprobe ultrasonography, spiral CT and MRI[J]. World J Gastroenterol,2003,9(2):219-224.
[128]顾雅佳,王玖华,相加庆,等.CT观察胸段食管癌气管食管沟淋巴结转移的临床意义探讨[J].中华放射学杂志,2002,36(2)：139-141.
[129]Lowe VJ, Booa F, Fletcher JG, et al. Comparion of positron emission tomography, computed tomography and endoscopic ultrasound in the initial staging patients with esophageal cancer[J]. Mol Imaging Biol,2005,7(6)-.422-430.
[130]李国仁,戴建华.食管癌淋巴结转移研究状况及其治疗策略[J].中国肿瘤,2007,16(11)：915-919.
[131]黄国俊.食管癌的定期、扩大淋巴结清扫及综合治疗[J].中华肿瘤杂志,2003,25(2)：105-110.
[132]Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma[J]. Cancer,2001, 92(3):663-669.
[133]Koide N, Nishio A, Kono T, et al. Histochernical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus[J]. Hepatogastroenterology,1999,46(26):952-958.
[134]Kosugi S, Nishimaki T, Nakagawa S, et al. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cacer patients[J]. World J Surg,2004, 28(7):680-685.
[135]Sako A, Kitayama J, Kaisaki S, et al. Hyperlipidemia is a risk factor for lymphatic metastasis in superficial esophageal carcinoma[J]. Cancer Lett,2004, 208(1):43-49.
[136]Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer[J]. Lancet,2002,359(9306):572-577.
[137]黄成,樊嘉,周俭,等.转移与无转移肝细胞癌患者血清蛋白指纹图谱的比较[J].中华实验外科杂志,2005,22(5)：550-552.
[138]冯笑山,王立东,单探幽,等.食管癌淋巴结转移的蛋白组学[J],郑州大学学报(医学版),2007,42(3)：397-399.
[139]汪斌,李俊材,傅仲学,等.食管鳞癌淋巴结转移的蛋白质组分析[J],重庆大学学报,2008,31(5)：587-592.
[140]Uemura N et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics[J]. Wiley Inter Science,2008,124:2106-2115.
[141]Hudson LG, Gale JM, Padilla RS, et al. Microarray analysis of cutaneous squamous cell carcinomas reveals enhanced expression of epidermal differentiation complex genes[J]. Mol Carcinog.2010 Jul;49(7):619-629.
[142]Yu Wang, Jisheng Li, Yan Cui, et al. Is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth through Inducing Apoptosis[J]. Cancer research,2009,69:5194.
[143]张昌明,张建龙,张琼,等.新疆汉族、维吾尔族及哈萨克族食管癌血清蛋白质指纹图谱[J].世界华人消化杂志.2010,18(17)：1173-1779.
[144]许洋.蛋白质指纹图谱技术在实验诊断与临床医学中的研究进展[J].基础医学与临床,2007,27(2)：134-142.
[145]Wulfkuhle JD, Paweltz CP, Steeg PS, et al. Proteomic approachs to the diagnosis, treatment, and monitoring of cancer [J]. Adv Exp Med Biol,2003,532:59-68.
[146]Smith FM, Gallagher WM, Fox E, et al. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy[J]. Ann Surg,2007,245(2):259-266
[147]Brockmann JG, St Nottberg H, Glodny B, et al. CYFRA 21-1 serum analysis in patients with esophageal cancer [J]. Clin Cancer Res,2000,6(11):4249-4252.
[148]Ychou M, Khemissa-Akouz F, Kralnar A, et al. A comparison of serum CYFRA21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma[J]. Cancer,2001,88(10):1023-1027.
[149]Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA21-1 determination in patients with esophageal squamons cell carcinoma:Clinical utility fo rdetection of recurrences [J]. Cancer,2000,89(7):1413-1417.
[150]Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal sqarnous cell cancer[J]. Br J Cancer,2005,93(1):107-115.
[151]Yamamoto M, Tsujinaka T, ShiozakiH, et al. Metallothionein expression correlates with the pathological response of patients with esophageal cancer underging preoperative chemoradiation therapy [J]. Oncology,1999,56(4):332-337.
[152]Matsumoto S, Yamada Y, Narikiyo M, et al. Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas[J]. Anticancer Res,2007; 27 (4B):2409-2414.
[153]Kii T, Takiuchi H, Kawabe S, et al. Evaluation of prognostic factors of esophageal squamous cell carcinoma (stagell-Ⅲ) after concurrent chemoradiotherapy using biopsy spceimens[J]. Jpn J Clin Oncol,2007,37(8):583-589.
[154]Hanunoud ZT, Badve S, Saxena R, et al. A novel biomarker for the detection of esophageal adenocarcinoma[J]. J Thorac Cardiovasc Surg,2007,133(1),82-87.
[155]Alici S, Uqras S, Bayram I, et al. Prognostic factors and COX-2 expression inadvanced stage esophageal squamous cell carcinoma[J]. Adv Ther,2006, 23(5):672-679.
[156]Jazii FR, Najafi Z, Malekzadeh R, et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer[J]. World J Gastroenterol,2006,12(44):7104-7112.
[157]Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors[J]. Int J Radiat Oncol Biol Phys,2008,72(2):398-403.
[158]An JY, Fan ZM, Zhuang ZH, et al. Proteomic analysis of blood level of proteins before and after operation in patients with esophageal squamous cell carcinoma at high-incidence area in Henan Province [J]. World J Gastroenterol,2004,10(22): 3365-3368.
[159]Zhang LY, Ying WT, Mao YS, et al. Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches[J]. World J Gastroenterol,2003,9(4):650-654.
[160]Coussens LM, Werb Z. Inflammation and cancer[J]. Nature,2002,420:860-867.
[1]Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990[J]. Int J Cancer,1999,80(6):827-841.
[2]Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990[J]. Int J Cancer,1999,83(1):18-29.
[3]段纪俊,陈万青,张思维.中国恶性肿瘤死亡率的国际比较[J].中国社会医学杂志,2009,26(6)：377-378.
[4]Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007[J]. CA Cancer J Clin, 2007,57(1):43-66.
[5]Wei JT, Shaheen N. The changing epidemiology of esophageal adenocarcinoma[J]. Semin Gastrointest Dis,2003,14(3):112-127.
[6]Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence[J]. J Natl Cancer Inst,2005, 97(2):142-146.
[7]Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years[J]. Ann Surg,2000,232(2):225-232.
[8]Whooley BP, Law S, Murthy SC, et al. Analysis of reduced death and complication rates after esophageal resection[J]. Ann Surg,2001,233(3):338-344.
[9]Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer [J]. Surg Clin North Am,2002,82(4):729-746.
[10]彭先娥,史习瞬.应用趋势面探索食管癌死亡率的地理分布特征[J].海峡预防医学杂志,2003,9(2)：66-67.
[11]王国清,魏文强,乔友林.食管癌筛查和早诊早治的实践与经验[J].中国肿瘤,2010,19(1)：4-8.
[12]王国清,郝长青,魏文强.内镜下黏膜切除术治疗早期食管癌和癌前病变长期生存率观察[J].中华消化内镜杂志,2008,25(11)：584-586.
[13]邵令方,高中人,李章才,等.204例早期食管癌和贲门癌切除治疗的远期结果[J].中华外科杂志,1993,31(3)：131-133.
[14]Wang GQ, Jiao GG, Chang FB, et al. Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening[J]. Ann Thorac Surg,2004,77(5):1740-1744.
[15]Veale RB, Thornley AL, Scott E, et al. Quantitation of autoantibodies to cytokeratins in sera from patients with squamous cell carcinoma of the oesophagus[J]. Br J Cancer,1988,58(6):767-772.
[16]刘保池,王立东,裴辉,等.食管癌肿瘤相关自身抗体检测[J].临床和实验医学杂志,2007,6(6)：3-5.
[17]Shimada H, Kuboshima M, Shiratori T, et al. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma[J]. Int J Oncol,2007, 30(1):97-103.
[18]Shimada H, Nakashima K, Ochiai T, et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma[J]. Int J Oncol,2005, 26(l):77-86.
[19]Shimada H, Takeda A, Arima M, et al. Serum p53ant ibody is auseful tumor marker in superficial esophageal squamous cell carcinoma[J]. Cancer,2000, 89(8):1677-1683.
[20]Shimada H, NABEYAY, OKAZUMIS, et al. Increased serum midkine concentration as a possible tumormarker in patients with superficial esophageal cancer[J]. Oncol Rep,2003,10(2):411-414.
[21]王永兴,苏伟,许建林,等.食管癌肿瘤标志物检测的临床应用[J].现代肿瘤学,2006,14(5)：570-571.
[22]张爱敏,焦晓青,张鹏.五项肿瘤标志物联合检测对食管癌诊治的临床评价[J].标记免疫分析与临床,2008,15(2)：65-67.
[23]陈怀霞,李育涛.多项肿瘤标志物在80例食管癌诊断中的应用分析[J].中国医药导报,2010,7(2)：181-182.
[24]杨忠信,赵松.食管癌患者围术期监测血清CEA CA125.CA199和β-HCG的临床意义[J].中国老年医学杂志,2010,30(4)：466-468.
[25]李波波,李道堂,刘曙光,等.食管癌患者血清中DKK-1的表达[J].山东大学学报(医学版),2009,47(6)：58-61.
[26]俞军,周晓明,何晓松,等.食管癌患者外周血中CK19mRNA, CYFRA21-1 TPS联合检测的临床意义[J].实用老年医学,2009,23(6)：464-469.
[27]Simeda Y, Imamura M, Watanabe G, et al. Prognostic factors of oesophageal cell carcinoma from th e perspect ive ofmolecu lar b iology[J]. Br J Cancer,1999, (8):1281.
[28]Liu YS, Yu CH, Li L, et al. Express ion of p53, p16 and cyclooxygenase-2 in esophageal can cer w ith t issue m icroarray[J]. J Dig Dis,2007,8(4):222.
[29]靳玉兰,张伟,刘伯齐,等.食管癌前病变及原位癌组织中Ki67, P53, iNOS的 异常表达[J].中华肿瘤杂志,2001,23(2)：129-131.
[30]毛友生,赵晓航,张德超,等.食管癌肿瘤标志物研究进展[J].世界华人消化杂志,2002,10(11)：1321-1323.
[31]Shimada H, Okazumi S, Takeda A, et al. Presence of serum p53antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer[J]. Surg Today,2001,31(7):591-596.
[32]Takahashi K, Miyashita M, Nomura T, et al. Serum p53antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma[J]. Dis Esophagus,2007,20(2):117-122.
[33]Ewen ME, Sluss HK, Sherr CJ, et al. Functional interact ions of the ret inob lastoma protein with mammalian D-type cyclines[J]. Cell,1993,73(3):487-497.
[34]Sorsdah 1K, Casson AG, Troster M, et al. P53and ras gene expression in human esophageal cancer and Barrentts epitheliumra prospective study[J]. Cancer Dete and Prev,1994,18(3):179-185.
[35]刘莺,李克,刘文静,等DAPK mRNA和蛋白在食管鳞癌组织中的表达及意义[J].世界华人消化杂志2009,17(31)：3218-3222.
[36]王皓,钟理,王建飞,等.肿瘤标志物在食管鳞状细胞癌中的研究与应用[J].世界华人消化杂志,2009,17(18)：1842-1848.
[37]祁敏,魏显招,吴爱群.食管癌的表观遗传学与防治研究进展[J].医学研究杂志,2009,38(11)：20-23.
[38]Tycko B. Epigenetic gene silencing in cancer [J]. J Clin Invest, 2000,105(4):401-407
[39]Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation:a fundamental aspect of neoplasia[J]. Adv Cancer Res,1998,72:141-196
[40]Ehrlich M. DNA methylation in cancer:too much, but also too little[J]. Oncogene, 2002,21(35):5400-5413.
[41]Guo M, Ren J, House MG, et al. Accumulation of promotermethylation suggests epigenetic progression in squamous cell carcinoma of the esophagus[J]. Clin Cancer Res,2006,12(15):4515-4522.
[42]Guo M, House MG, Akiyama Y, et al. Hypermethylation of the GATA gene family in esophageal cancer[J]. Int J Cancer,2006,119(9):2078-2083.
[43]Bian YS, OsterheldMC, Fontolliet C, et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neop lastic progression in Barrett's esophagus[J]. Gastroenterology,2002,122(4):1113-1121.
[44]GuoM, HouseMG, Suzuki H, et al. Ep igenetic silencing of CDX2 is a feature of squamous esophageal cancer[J]. Int J Cancer,2007,121 (6):1219-1226.
[45]Abbaszadegan MR, Raziee HR, Ghafarzadegan K, et al. Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma[J]. Int J Gastrointest Cancer,2005,36(1):47-54.
[46]Tzao C, Hsu HS, Sun GH, et al. Promotermethylation of the hMLH1 gene and p rotein exp ression of human mutL homolog 1 and human mut S homolog 2 in resected esophageal squamous cell carcinoma[J]. J Thorac Cardiovasc Surg,2005, 130(5):1371.
[47]Kuroki T, Trapasso F, Yendamuri S, et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FH IT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma[J]. Cancer Res, 2003,63(13):3724-3728.
[48]Smith E, Drew PA, Tian ZQ, et al. Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation[J]. Mol Cancer,2005,13(4):42.
[49]Guo M, House MG, Akiyama Y, et al. Hypermethylation of the GATA gene family in esophageal cancer[J]. Int J Cancer.2006,119(9):2078-83.
[50]Tokugawa T, Sugihara H, Tani T, el al. Modes of silencing of p16 in development of esophageal squamous cell carcinoma[J]. Cancer Res,2002,62(17):4938-4944.
[51]Abbaszadegan MR, Raziee HR, Ghafarzadegan K, et al. Aberrant p16 methylation, a possible epigenetic risk factor in fam ilial esophageal squamous cell carcinoma[J]. Int JGastro intes t Cancer,2005,36(1):47-54.
[52]Ling Y, Huang G, Fan L, et al. CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma[J]. J Clin Pathol.2011,64(3):246-51.
[53]肖志平,刘冉,许婧,等.DNA修复酶基因MGMT启动子区异常甲基化与食管癌的关系[J].癌变.畸变.突变,2009,21(2)：105-108.
[54]Kim YT, Park JY, Jeon YK, et al. Aberrant promoter CpG island hypeanethylation of the adenanatosis polyposis coli gene can serve as a good pmgnostic factorhy affectnig lymph nodemetastasis in squamous cell carcinoma a of the espphagus[J]. Dis Esophagus,2009,22(2):143-150.
[55]Zare M, Jazii FR, Alivand MR, et al. Qualitative analysis of Adenomatous Polyposis Coli promoter:hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker[J]. BMC Cancer,2009,9:24.
[56]缪辉来,杜水洁,林木生,等.原发性肝细胞癌中错配修复基因hMLHl的表达及其意义[J].中华实验外科杂志,2005,22：435-436.
[57]Kane MH, Loda M, Gaida GM, et al. Methylation of the hMLHl promoter correlates with lack of expression of hMLHl in sporadic colon tumors and mismatch repair-defectiee human tumor cell lines[J]. Cancer Res, 1997,57(5):808-811.
[58]Yao Y, Tao H, Kim JJ, et al. Alterations of DNA mismatch repair proteins and microsatellite instability levels in gastric cancer cell lines[J]. Lab Invest, 2004,84(7):915-922
[59]Vasavi M, Kiran V, Ravishankar B, et al. Microsatellite instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers[J]. Cancer Biomark,2010,7(1):1-10.
[60]丛德刚,王胜发.食管癌组织RASSF1A基因启动子区甲基化检测及其临床意义[J].中华医学杂志,2007,87(41)：2932-2934.
[61]Lee OJ, Schneider-Stock R, McChesney P A, el al. Hypermethylalion and Loss of expression of glutathione peroxidase-3 in Barren's tumorigenesis[J]. NeopLasia, 2005,7(9):854-861.
[62]Tzao C, Sun GH, Tung HJ, et al. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma[J]. Ann Thorac Surg.2006,82(2):396-401.
[63]Dutsch-wicherek M, Sikora J, Tomaszewska R. The possible biological role of metallothionein in apoptosis[J]. Front Biosci,2008,13(9):4029-4038.
[64]Smith E, Drew PA, Tian ZQ, et al. Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation[J]. Mol Cancer,2005,4:42.
[65]田子强,刘俊峰,张月锋,等.食管鳞状细胞癌中MT-3基囚GpG岛甲基化及其临床意义[J].实用肿瘤杂志,2004,19(5)：386-389.
[66]田子强,李勇,刘俊峰,等.食管癌新鲜肿瘤组织中MT-3基因CpG岛甲基化的临床意义[J].中国肿瘤临床,2008,35(20)：1180-1183.
[67]解明然,林鹏.蛋白质组学及其在食管癌中的应用[J].国际肿瘤学杂志,2009,36(12)：437-439.
[68]刘茶珍,朱佩云,施民新,等.表达蛋白质组学技术及其在食管癌研究中的进 展[J].环境与职业医学,2006,23(2)：158-160.
[69]张昌明,伊力亚尔.夏合丁,张建龙.蛋白质组学技术及其在食管癌中的研究进展[J].新疆医科大学学报,2010,33(2)：212-214.
[70]Enzinger PC, Mayer RJ. Esophageal cancer[J]. N Engl J Med,2003,349(23):2241-2252.
[71]Xiong XD, Xu LY, Shen ZY, et al. Identification of differentially expressed proteins between human esophageal immortalized andcarcinomatous cell 1 ines by two dimensional electrophoresis and MALDI-TOF-MS[J]. World J Gastroenterol, 2002,8(5):777-781.
[72]Xiong XD, Li EM, Xu LY, et al. Separation and identification of differentially expressed nuclear matrix proteins between human esophageal immortalized and carcinomatous cell lines[J]. World J Gastrognterol,2003,9(10):2143-2148.
[73]Qi YJ, He QY, Ma YF, et al. Proteomic identification of malignant transformation related proteins in esophageal squamous cell carcinoma[J]. J Cell Biol,2008,104 (5):1625-1635.
[74]牛保华,齐义军,曹世华,等.食管鳞癌恶性表型相关蛋白的蛋白质组学研究[J].肿瘤,2009,29(7)：611-615.
[75]Ostrowski J, Mikula M, Karczmarski J, et al. Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics[J]. J Mol Med,2007, 85(7):733-743.
[76]Flucke U, Steinborn E, Dries V, et al. Immunoreactivity of cytokeratins(CK7, CK20) and mucin peptide core antigens(MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach[J]. Histopathology,2003,43(3): 127-134
[77]Ormsby AH, Goldblum JR, Rice TW, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach[J]. Human Pathol,1999,30(3):288-294.
[78]Liu Z, Feng JG, Tuersun A, et al. Proteomic identification of differentially-expressed proteins in esophageal cancer in three ethnic groups in Xinjiang[J]. Mol Biol Rep,2010 Dec 2.[Epub ahead of print]
[79]Emmert-Buck MR, Gillespie JW, Paweletz CP, et al. An approach to proteomics analysis of human tumors[J]. Mol Carcinog,2000,27(3):158-165.
[80]Zhou G, Li HM, Gong Y, et al. Proteomic analysis of global alteration of protein expression in squamous cell carcinoma of the esophagus[J]. Proteomics,2005, 5(14):3814-3821.
[81]汪斌,李俊材,傅仲学,等.食管鳞癌淋巴结转移的蛋白质组分析[J].重庆医科大学学报,2008,31(5)：587-591.
[82]Tutuian R. Update in the diagnosis of gastroesophageal reflux disease[J]. J Gastrointestin Liver Dis,2006,15(3):243-247.
[83]Zhao J, Chang AC, Li C, et al. Comparative proteomics analysis of Barrett Metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping[J]. Mol Cell Proteomics,2007,6(6):987-999.
[84]任涛,胡建明,刘春霞,等RASSF1A基因启动子甲基化与新疆哈萨克族食管癌的相关性研究[J].农垦医学,2009,31(6)：481-486.
[85]Liotta LA, Petricoin EF. Serum peptidome for cancer detection:spinning biologic trash into diagnostic gold[J]. J Clin Invest,2006,116(1):26-30.
[86]Zhang H, Liu AY, Loriaux P, et al. Mass spectrometric detection oft issue proteins in plasma[J]. Mol Cell Proteomics,2007,6(1):64-71.
[87]Liu LH, Shan BE, Tian ZQ, et al. Potential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry[J]. Clin Chem Lab Med,2010,48(6):855-861.
[88]任兴军,谭小林,杨成虎,等.食管癌血清蛋白质谱指纹图分析及人工神经网络诊断模型研究[J].现代检验医学杂志,2010,25(3)：22-26.
[89]谭小林,王开正,胡琼英,等.食管癌血清蛋白质谱指纹图分析及人工神经网络诊断模型研究[J].现代检验医学杂志,2010,25(3)：27-30.
[90]刘丽华,单保恩,王士杰,等.食管癌患者血清蛋白指纹图谱的检测及食管癌诊断模型的建立[J].中国肿瘤生物治疗杂志,2009,16(3)：272-276.
[91]单探幽,冯笑山,王立东,等.责门癌蛋白质组与病理分化程度的研究[J].中华肿瘤防治杂志,2007,14(5)：373-376.
[92]徐淑永,张琼,张朝霞,等.新疆维吾尔族食管癌患者血清蛋白指纹图谱诊断模型的建立[J].新疆医科大学学报,2008,31(2)：154-156.
[93]Xu SY, Liu Z, Ma WJ, et al. New potential biomarkers in the diagnosis of esophageal squamous cell carcinoma[J]. Biomarkers,2009,14(5):340-6.
[94]张昌明；张建龙；张琼,等.新疆汉族、维吾尔族及哈萨克族食管癌血清蛋白质指纹图谱[J].世界华人消化杂志,2010,18(17)：1773-1779.
[95]Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research:practical advices[J]. Expert Rev Proteomics,2007,4(1):51-65.
[96]Finn OJ. Immune response as a biomarker for cancer detection and a lot more[J]. N Engl J Med,2005,353(12):1288-1290.
[97]Fujita Y, Nakanishi T, Miyamoto Y, et al. Proteomics_based identification of autoantibody against heat shock protein 70 as a diagnost ic marker in esophageal squamous cell carcinoma[J]. Cancer Lett,2008,263(2):280-290.
[98]Fujita Y, Nakanishi T, Hiramatsu M, et al. Proteomics based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma[J]. Clin Cancer Res,2006,12(21):6415-6420.
[99]Fu L, Qin YR, Xie D, et al. Identificat ion of alpha-actinin 4 and 67kDa laminin receptor as stage_specific markers in esophageal cancer via proteomic app-roaches[J]. Cancer,2007,110(12):2672-2681.
[100]安继业,秦艳茹,庄则豪,等.河南食管癌高发区同一患者食管癌手术前后血清蛋白质组变化分析[J].中国综合临床,2006,22(11)：1026-1028.
[101]Cai Z, Zhou Y, Lei T, et al. Mammary serine protease inhibitor inhibits epithelial growth factor induced epithelial esenchymal transition of esophageal carcinoma cells[J]. Cancer,2009,115(1):36-48.
[102]Jazii FR, Najafi Z, Malekzadeh R, et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer[J]. World J Gastroenterol,2006,12(44):7104-7112
[103]Uemura N, Nakanishi Y, Kato H, et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics[J]. Int J Cancer,2009, 124(9):2106-2115.
[104]Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics[J]. Biomarker Insights,2006,2(1):1-48.
[105]Harris L, Fritsche H, Mennel R, et al. Americian Society of Clinical Oncology 2007 update of recommendat ions for the use of tumor markers in breast cancer[J]. J Clin Oncol,2007,25(33):5287-5312.
[106]Vallbohmer D, Brabender J, Metzger R, et al. Genetics in the pathogenesis of esophageal cancer:possible predictive and prognostic factors[J]. J Gastrointest Surg.2010,14 Suppl 1:S75-80.
[2]Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden:Globocan 2000[J]. Int J Cancer,2001,94(2):153-156.
[3]Layke JC, Lopez PP. EsoPhageal cancer:a review and update[J]. Am Fam Physician,2006,73(12):2187-2194.
[4]汤钊猷.现代肿瘤学[M].2版.上海：复旦大学出版社,2000：20-25.
[5]Holmes RS, TL Vaughan. Epidemioloy and pathogenesis of esophageal cancer[J]. Semin Radiat Oncol,2007,17(1):2-9.
[6]Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007[J]. CA Cancer J Clin,2007, 57(1):43-66.
[7]Valberg PA, Long CM, Sax SN, et al. Integrating studies on carcinogenic risk of carbon black:epidemiology, animalexposures and mechanism of action[J]. J Occup Environ Med,2006.48(12):1291-1307.
[8]邹小农.食管癌流行病学[J].中华肿瘤防治杂志,2006,13(18)：181-184.
[9]林东昕.中国食管癌分子流行病学研究[J].中华流行病学杂志2003,24(10)：939-943.
[10]周福有,王立东.食管癌早期诊断方法的哲学思考[J].医学与哲学(临床决策论坛版).2008,10(29)：69-72.
[11]侯浚.食管癌的防治流行病学[J].食管外科,2007,6(1)：16-21.
[12]李连弟,鲁风珠,牧人,等.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1)：3-9.
[13]陈伟三,杨合麟.广东南澳县1987-1992年食管癌流行病学特点[J].癌症,1996,15(4)：274-276.
[14]Wang LD, Zheng S. The mechanism of esophageal and gastric cardia carcinogenesis from the subjects at high-incidence area for esophageal cancer in henna[J]. Zhengzhou daxue xuebao,2002,37(6):717-729.
[15]Rose EF. Cancer of oesophagus [J]. S Afr J Hosp Med,1978,4(2):110.
[16]Yang PC, Davis s.Incidence of cancer of the esophagus in the U. S. by histolgic type[J]. Cancer,1988,61(3):612-617.
[17]Blot WJ, Fraumeni JF.Trends in esophagus cancer mortality among U. S. blacks and whites[J]. Am J Public Health,1987,77(3):296-298.
[18]杨文献.食管癌的流行病学特征[M].见：杜百廉,食管癌,北京：中国科学技术出版社,1994,34-35.
[19]Zhang YM. Distribution of esophageal cancer in xinjiang[J]. Xinjiang yixueyuan xuebao,1988,11 (2):139-144.
[20]王秀梅,杰恩斯,马彦清.新疆哈萨克族食管癌危险因素病例对照研究[J].中国公共卫生.2007,23(6)：737-738.
[21]平育敏,张以德,杜喜群,等.食管癌和责门癌20000例外科治疗经验[J].见：中国首届国际食管癌学术会议暨第七届全国食管癌学术会议论文集.2005：161-171.
[22]邵令方,高崇人,许金良,等.管癌和贲门癌外科治疗15707例总结----附河南省食管癌的防治研究概况[J].见：中国首届国际食管癌学术会议暨第七届全国食管癌学术会议论文集.2005：40-45.
[23]Tachibana M, Kinugasa S, Shibakita M, et al. Review;Surgical treatment of superficial esophageal cancer[J]. Langenbeck Arch Surg,2006,391(4):304-321.
[24]邵令方,高宗人,李章才,等.204例早期食管癌和责门癌切除治疗的远期结果[J].中华外科杂志,1993,31(3)：131-133.
[25]Wang GQ, Jiao GQ, Cheng FB, et al. long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening[J]. Ann Thorac Surg,2004,77(5):1740-1744.
[26]张合林,平育敏,杜喜群,等.应用Cox模型分析影响食管癌切除术后预后因素[J].中华肿瘤杂志,1999,21(1)：32-34.
[27]张合林,平育敏,白世祥,等.食管鳞癌淋巴结转移对预后影响的分析[J].中国肿瘤临床,2001,28(5)：340-343.
[28]李国仁,戴建华.食管癌淋巴结转移研究状况及其治疗策略.中国肿瘤,2007,16(1)：915-919.
[29]刘巍,陈勇.食管癌淋巴结转移相关研究[J].中国肿瘤临床,2008,35(21)：1253-1260.
[30]Hsu CP, Chen CY, Hsia JY, et al. Prediction of prognosis by theextent of lymph node involvement in squamous cell carcinoma of the thoracic esophagus [J]. Eur J Cardiothorac Surg,2001,19(1):10-13.
[31]Pearson FG, Cooper JD, Deslauriers J, et al. Esophageal Surgery [M]. Heal Science Asia, Elsevier Science,2002,714.
[32]Akiyama H, Tsurumaru M, Udagawa H, et al. Radical lymph node dissection for cancer of the thoracic esophagus[J]. Ann Surg,1994,220(3):364-372.
[33]Nakajima Y, Nagai K, Miyoke S, etal. Evaluation of metastasis of esophageal squamous cell carcinoma invading the submucosal layer[J]. Jpn J Cancer Res, 2002,93(3):305-312.
[34]Araki K, Ohno S, Egashira A. et al. Pathologic features of superfecial esophageal squmous cell carcinoma with lymphnode and distal metastasis[J]. Cancer,2002, 94(2):570-575.
[35]Kodama M, Kakagama T. Treatment of superficial cancer of the thoracic esophagus:A summary of responses to a questionnaire on superficial cancer of the esophagus in Japan[J]. Surgery,1998,123(4):432-439.
[36]许运龙,郭昭扬.胸部食管癌转移淋巴结数与预后的临床研究[J].中华肿瘤杂志,2000,22(3)：244-246.
[37]Shimada H, Okazumi S, Matsubara H, et al. Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymphnode dissection[J]. World J Surg,2006, 30(8):1441-1449.
[38]Nakamura T, Ide H, Eguchi R, et al. Clinical implications of lymph node micrometastasis in patients with histologically node-negative(pNO)esophageal carcinoma[J]. J Surg Oncol,2002,79(4):224-229.
[39]Sato F, Shimada Y, Li Z, et al. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma [J]. Br J Surg,2001, 88(3):426-432.
[40]Igaki H, Tachimori Y, Kato H. Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection[J]. Ann Surg,2004, 239(4):483-490.
[41]Tabira Y, Kitamura N, Yoshioka M, et al. Significance of three-field lymphadenectomy for carcinoma of the thoracic esophagus based on depth of tumor infiltration, lymph nodal involvement and survival rate[J]. J Cardiovasc Surg(Torino),1999,40(5) 737-740.
[42]Law S, Wong J. Two-field dissection is enough for esophageal cancer[J]. Dis Esophagus,2001,14(2):98-103.
[43]Nozoe T, Kakeji Y, Baba H, et al. Two-field lymph-node dissection may be enough to treat patients with submucosal squamous cell carcinoma of the thoracic esophagus[J]. Dis Esophagus,2005,18(4):226-229.
[44]王洲,刘相燕,刘凡英,等.N0期食管癌术后早期复发与淋巴结微转移的相关性研究[J].中华外科杂志,2004,42(2)：68-71.
[45]Shiozkai H, Doki Y, Kawnaishi K, et al. Clinical application of malignancy potential grading as a prognostic acftor of human esophageal cancers[J]. Surgery, 2000,127(5):552-561.
[46]Stoop AA, Jespers L, Lasters T, et al. High-denisty mutagenesis by combined DNA shuffling and phage display to assign essential amino acid in Protein—Protein interaction:application to study structure function of plas minogen activation inhibitor. [J]. MolBiol,2000,301(5):1135-1147.
[47]Broemknna JG, St Nottberg H, Glodny B, et al. CYFRA21-1 Serum analysis in patients with esophageal cancer[J]. Clin Cancer Res,2000,6(11):4249-4252.
[48]Ychou M, Khemissa-AkouzF, Krmaar A, et al. A comparison of seurm Cyfra 21-1 and SCC AG in the diagnosis of squmaous cell esophageal carcinoma[J]. Bull Cancer,2001,88(10):1023-1027.
[49]Kwauguchi H, Ohno S, Miyazkai M, et al. CYFRA21-1 detection in patients with esophageal squmaous cell carcinoma:clinical utiliy for detection of recurrences[J]. Cancer,2000,89(7):1413-1417.
[50]Ikeguchi M, Oka S, Gomyo Y, et al. Combined analysis of p53and retinoblastoma protein exepressions in esophageal cancer[J]. Ann Thorac Surg,2000,70(3):913-917.
[51]Banks RE, Dunn MJ, Hochstrasser DF, et al. Proteomics:new perspectives, new biomedical opportunities. Lancet,2000,356(9243):1749-1756.
[52]Arrell DK, Neverova I, Van Eyk JE. CardiovascularProteomics:evolution and potential[J]. CircRes,2001,88(8):763-773.
[53]Wasinger VC, Cordwell SJ, Cerpa-Poljak A, et al. Progress with gene-product mapping of the Mollicutes:Mycoplasma genitalium [J]. Electrophoresis,1995, 16(7):1090-1094
[54]Li J, ZhangZ, Rosenzweig J, eta.1 Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer[J]. Clin-Chem,2002, 48(8):1296-1304.
[55]QiY, Chiu JF, Wang L, et al. Comparative proteomic analysis of esophageal squamous cell carcinoma [J]. Proteomics,2005,5(11):2960.
[56]Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor:a heat activated ion channel in the pain pathway[J]. Nature,1997,389(6653):816.
[57]Hoffinann P, Ji H, Moritz RL, et al. Continuous free-flow electorphoersis of cytosolic proteins from the human colon cacrinoma cell line LIM1215:a non two-dimensional gel electrophoresis-based proteome annalysis strategy [J]. Proteomics,2002,1(7):807-818.
[58]Hutchens TW, Yip TT. New desoprtion srtategies of the mass specrtomic analysis of macromolecules[J]. Rpaid Commun Mass specrtom,1993,7(7):576-580.
[59]Weinberger SR, Morris TS, Pawlak M. Recent trends in protein biochip technology [J]. Pharmacogenomics,2000,1(4):395-416.
[60]Vlahou A, Laronga C, Wilson L, et al. A novel approch toward development of a rapid blood test for breast cancer[J]. Clin Breast Cnacer.2003,4(3):203-209.
[61]von Eggeling F, Davies H, Lomas L, et al. Tissue-specific microdissection coupled with proetinchip array technologies:applications in cancer research[J]. Bio Techniques,2000,29(5):1066-1070.
[62]Pwaeletz CP, Trock B, Pennanen M, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF:potential for new biomakrers to aid in the diagnosis of breast cancer[J]. Dis Markers,2001,17(4):301-307.
[63]Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis associated protein I as a biomarker for pnacreatic ductal adenocarcinoma by protein biochip technology [J]. Cancer Res,2002,62(6):1865-1575.
[64]Vlahou A, Sehellhammer PF, Mendrinos S, et al. Development of a noval proteomics approach for the detection of transitional cell carcinoma of bladder in urine[J]. Am J Pathol,2001,158(4):1491-1502.
[65]Mannes AJ, Martin BM, Yang HY, et al. Cystatin C as a eerebrospinal fluid biomaker for pain in humans[J]. Pain,2003,102(3):251-256.
[66]Beher D, Wrigley JD, Owens AP, et al. Generation of C-terminally truncated amayloid-beta peptides is dependent on gamma-secretase activity[J]. J Neurochem, 2002,82(3):563-575.
[67]Clarke W, Silverman BC, Zhang S, et al. Characterization of renal allograft rejection by urinary proteomic analysis[J]. Ann Surg,2003,237(5):660-664.
[68]Qu Y, Adxna BL, Yasui Y, et al. Boosted decision tree analysis of surafce-enhanced laser desorption/ionization masss spectral serum profile discriminates Prostate cancer from noncancer patients[J]. Clin Chem,2002,48(10):1835-1843.
[69]Wright Jr GL, Cazares LH, Leung SM, et al. Proteinchip(R) surafce enhanced laser desorption/ionization(SELDI)mass spectrometry:a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures[J]. Prostate Cancer Prostatic Dis,1999,2(6):264-276.
[70]Adma BL, Qu Y, Dvais JW, et al. Serum protein fingerprinting coupled with a patter-matching algorithm distinguishes prostate cancer from benign prostatehyperplasia and and healhty men[J]. Cancer Res,2002,62(13):3609-3614.
[71]LI J, Zhnag Z, Rosenzweig J, et al. Proteomic and informatics approaches for identification of serum biomarkers to detect breast cancer[J]. Clinical Chemistry, 2002,48(8):1296-1304.
[72]Jones MB, Krutzsch H, Shu H, et al. Proetomic analysis and identification of new biomarkers and therapeutic targets for overian cancer[J]. Proteomics,2002, 2(1):76-84.
[73]Rai AJ, Zhnag Z, Rosenzweig J, et al. Proteomic apporaches to tumor marker discovery[J]. Arch Pathol Lab Med,2002,126(12):1518-1526.
[74]Xiao XY, Tang Y, Wei XP, etal. A preliminary analysis of non-small cell lung cancer biomarkers in serum[J]. Biomed Environ Sci,2003,16(2):140-148.
[75]Zhao X, Mao Y, Zhang L, et al. Porgram/Proceedings Supplement of American Association for Cancer Research.2002:79.
[76]Chen YD, Zheng S, Yu JK, et al. Artificial neural network analysis of surface-enhanced laser desoprtion/ionization mass spectra of seurm protein fingerprinting distiguishes colorectal cancer from healthy population. Clinical Cancer Res,2004,10(24):8380-8385.
[77]Wang YY, Zhang Z, White N, et al. Detection of cancer biomarkers by SELDI proteomics technology from serum in colorectal carcinoma[J]. Proceedings of the AACR, Toronio, Ontario, Canada,2003;44(3):6320.
[78]Cazares L, Wdasworth JT, Somers KD, et al. Serum protein expression profiles identify head and neck cancer [J]. Proceedings of the AACR, Toronio, Ontario, Canada,2003; 44(3):1521.
[79]White CN, Chan DW, Zhang Z. Bioinformatics strategies for Proteomic Profiling[J]. Clin Biochem,2004,37(3):636-641.
[80]Boguski MS, Meintosh MW. Biomedical informatics for Proteomics [J]. Nature, 2003,422(6928):233-237.
[81]Ball G, Mian S, Holding F, et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumor and rapid identification of potential biomarkers[J]. Bioinformatics,2002,18(3): 395-404.
[82]Narayanan A, Keedwell EC, Olsson B. Artificial intelligence techniques bioinformatics[J]. Appll Bioinformatics,2002,1 (4):191-192.
[83]余捷凯,郑树,唐勇,等.血清蛋白质谱与人工神经网络模型诊断卵巢癌的应用性研究[J].中华检验医学杂志,2005,25(5)：480-482.
[84]雷英杰,张善文,李续武,等MATLAB遗传算法工具箱及应用[M].西安：西安电子科技大学出版社,2005：11-16.
[85]张昌明,李德生,张海平,等.食管癌血清差异蛋白的研究[J].中华消化外科杂志,2010,9(6)：444-446.
[86]张昌明,张海平,张琼,等.新疆哈萨克族患者血清蛋白质指纹图谱分析.中华医学杂志,2011,91(3)：171-174.
[87]刘建,郑树,余捷凯,等.胶质瘤脑脊液蛋白指纹图质谱仪分析及其在临床诊断中的应用[J].中华神经外科,2004,20(5)：362-366.
[88]Chen G, Tarek TG, Huang CC, et al. Proteomicanalysis of lung adenocarcinoma: Identification of ahighly expressed set of proteins in tumors [J]. Clin Cancer Res, 2002,8(7):2298-2305.
[89]Qu YS, Adam BL, Yutaka Y, et al. Boosted Decision Tree analysis of Surface-enhanced Laser Desorption/Ionization mass spectral serum profiles discriminates prostate cancer from noncancer Patients[J]. Clin Chem,2002,48(10):1835-1843.
[90]陈益定,郑树,余捷凯,等.血清蛋白质质谱模型在大肠癌诊断中的应用[J].中华肿瘤杂志,2004,26(7)：381-383.
[91]王庆荣,张琼,张朝霞,等.新疆地区汉族、维吾尔族及哈萨克族食管癌血清蛋白质指纹图谱研究[J].临床检验杂志,2009,27(6)：195-197.
[92]Chan A, Wong A. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma? Int J Radiat Oncol Biol Phys,1999,45(2):265-270.
[93]安丰山,黄金球,谢映涛,等.食管癌新辅助放化疗的前瞻性临床研究[J].中华肿瘤杂志,2003,25(4)：376-379.
[94]Yang H, Berner A, Mei Q, et al. Cytologic screening for esophageal cancer in a high-risk population in anuang county[J]. China. Acta Cytol,2002,46(3);445-52.
[95]Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma[J]. Cancer,2002,94(4):921-928.
[96]宁国庆,袁宪顺,吕守臣,等.螺旋CT增强扫描对食管癌淋巴结转移的诊断价值[J].医学影像学杂志,2007,17(2)：148-151.
[97]Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer,100 consecutive position emission tomography scans[J]. Ann Thorac Surg,1999,68(4):1133-1136.
[98]Yoon YC, Eee KS, Shim YM, et al. Metastasis to regional lymph nodes in patients with esophageal squarnous cell carcinoma:CT versus FDG PET for presurgical detection prospective study[J]. Radiology,2003,227(3):764.-770.
[99]van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer.a meta-analysis[J]. BR J Cancer,2008,98(3):547-557.
[100]JinY, Zhang W, Liu B. et al. Abnomal expression of p53, Ki67 and iNOS in human esophageal carcinoma in situ and pre-malignant lesions P53[J]. Chinese J Oncology,2001,23(2):129-231.
[101]Zhang W, Rashid A, Wu H, et al. Dieffrential expression of retinoic acid receptors and p53protein in normal, premalignant, and malingnat esophageal tissues[J]. J Cancer Res Clin Oncol,2001,127(4):237-242.
[102]Shimada H, Takeda A, Arima M, et al. Serun p53antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma[J]. Cnacer,2000, 89(8):1677-1683.
[103]Brockmann JG, St Nottberg H, Glodny B, et al. CYFRA2-1 Serum analysis in patients with esophageal cancer[J]. Clin Cancer Res,2000,6(11):4249-4252.
[104]Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA21-1 determination in patients with esophageal squmaous cell carcinoma:clinical utility for detection of recurrences [J]. Cancer,2000,89(7):1413-1417.
[105]Yang EC, Guo J, Diehl G, et al. Protein expression profiling of endometrial malingnacies reveals a new tumor marker:chaperonin1O[J]. J Porteome Res,2004, 3(3):636-643.
[106]施民新,刘茶珍,刘继斌,等.应用SELDI-TOF-MS技术分析南通地区食管癌血清差异表达蛋白[J].现代肿瘤医学,2006,14(11)：1360-1361.
[107]刘茶珍,朱佩云,施民新,等.应用IMAC3蛋白芯片分析食管鳞癌患者血清蛋白质谱的变化[J].癌症,2008,27(3)：272-278.
[108]Xu SY, Liu Z, Ma WJ, et al. New potential biomarkers in the diagnosis of esophageal squamous cell carcinoma[J]. Biomarkers,2009,14(5):340-346.
[109]Albethsen J, Bogebo R, Olsen J, et al. Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum[J]. Clin Chem Lab Med,2006,44(10):1243-1252.
[110]Malle E. Sodin Semrl S,Kovacevic A, et a.l Serum amyloid A:an acute-phase protein involved in tumour pathogenesis[J].Cell Mol Life Sc,i 2009,66(1):9-26.
[111]Urieli-Shoval S,Shubinsky G,Linke RP,et al. Adhesion of human platelets to serum amyloid A[J].Blood,2002,99(4):1224-1229.
[112]Wood SL, Rogers M, Cairns DA,et al. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. British Journal of Cancer[J], 2010,103(1),101-111
[113]Michaeli A,Finci-Yeheskel Z,Dishon S,et al.Serum amyloid A enhances plasm inogenactivation:implication for a role in colon cancer[J].Biochem Biophys Res Commun,2008,368(2):368-373.
[114]Freeman MR, Solomon KR. Cholesterol and Prostate cancer[J]. J Cell Biochem, 2004,91(1):54-69.
[115]Myers RB, Oelschlager DK, Weiss HL, et al. Fatty acid synthase:a nearly molecular maker of progression of prostastic adenomalignant to androgen independence[J]. J Urol,2001,165(3):1027-1032.
[116]Trougakos IP, GonosES. Clusterin/Apolipoprotein J in human aging and cancer[J]. Int J Biochem Cell Biol,2002,34(11):1430-1448.
[117]Malik G, Ward MD, Gupta SK, et al. Serum Levels of an isoform of apolipoprotein A-11 as a potential marker for prostatc cancer[J]. ClinCancer Res,2005, 11(3):1073-1085.
[118]Funahashi T, Yokoyama S, Yamamoto A. Association of apolipoprotein with the low-density lipoprotein receptor:demonstration particles[J]. J Biochem,1989, 105(4):582-587.
[119]Park W.-R., Nakamura Y. p53CSV, a novel p53-inducible gene involved in the p53-dependent cell-survival pathway[J]. Cancer Res.2005,65(4):1197-1206.
[120]Oda K, Arakawa H, Tanaka T, et al. p53AIPl, a potential media-tor of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53[J]. Cell, 2000,102(6):849-862.
[121]Seam N, Gonzales D A, Kern S J, et al. Quality control of serum albumin depletion forproteomic analysis[J]. Clin Chem,2007,53(11):1915-1920.
[122]Rollin D, Whistler T, Vernon SD. Laboratory methods to improve SELDI peak detection and quantitation[J]. Proteomc Sci,2007,5:9-14.
[123]黄国俊.外科手术在胸部恶性肿瘤治疗中的地位[J].中华外科杂志,2003,41(6)：401-403.
[124]Robinson JC, Kerjan P, Mirands M. Meromolecular assemblage of aminoacy tRNA synthetasses:quantitative analysis of protein-protein interactions and mechanism of complex assembly[J]. J Mol Biol,2000,304(5):983-994.
[125]Stoop AA, Jespers L, Lasters T, et al. High-denisty mutagenesis by combined DNA shuffling and Phage display to assign essential amino acid in protein-protein interaction:application to study structure function of plas minogen activation inhibitor[J]. Mol Biol,2000,301(5):1135-1147.
[126]Lu ZM, Zhang H, Wang MH, et al. Lymphatic metastasis intensity of and lymphadenectomy for thoracic esophageal squamous cell carcinoma[J]. AiZheng, 2006,25(5):604-608.
[127]Wu LF, Wang BZ, Feng JL, et al. Preoperative TN staging of esophageal cancer:comparison of miniprobe ultrasonography, spiral CT and MRI[J]. World J Gastroenterol,2003,9(2):219-224.
[128]顾雅佳,王玖华,相加庆,等.CT观察胸段食管癌气管食管沟淋巴结转移的临床意义探讨[J].中华放射学杂志,2002,36(2)：139-141.
[129]Lowe VJ, Booa F, Fletcher JG, et al. Comparion of positron emission tomography, computed tomography and endoscopic ultrasound in the initial staging patients with esophageal cancer[J]. Mol Imaging Biol,2005,7(6)-.422-430.
[130]李国仁,戴建华.食管癌淋巴结转移研究状况及其治疗策略[J].中国肿瘤,2007,16(11)：915-919.
[131]黄国俊.食管癌的定期、扩大淋巴结清扫及综合治疗[J].中华肿瘤杂志,2003,25(2)：105-110.
[132]Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma[J]. Cancer,2001, 92(3):663-669.
[133]Koide N, Nishio A, Kono T, et al. Histochernical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus[J]. Hepatogastroenterology,1999,46(26):952-958.
[134]Kosugi S, Nishimaki T, Nakagawa S, et al. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cacer patients[J]. World J Surg,2004, 28(7):680-685.
[135]Sako A, Kitayama J, Kaisaki S, et al. Hyperlipidemia is a risk factor for lymphatic metastasis in superficial esophageal carcinoma[J]. Cancer Lett,2004, 208(1):43-49.
[136]Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer[J]. Lancet,2002,359(9306):572-577.
[137]黄成,樊嘉,周俭,等.转移与无转移肝细胞癌患者血清蛋白指纹图谱的比较[J].中华实验外科杂志,2005,22(5)：550-552.
[138]冯笑山,王立东,单探幽,等.食管癌淋巴结转移的蛋白组学[J],郑州大学学报(医学版),2007,42(3)：397-399.
[139]汪斌,李俊材,傅仲学,等.食管鳞癌淋巴结转移的蛋白质组分析[J],重庆大学学报,2008,31(5)：587-592.
[140]Uemura N et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics[J]. Wiley Inter Science,2008,124:2106-2115.
[141]Hudson LG, Gale JM, Padilla RS, et al. Microarray analysis of cutaneous squamous cell carcinomas reveals enhanced expression of epidermal differentiation complex genes[J]. Mol Carcinog.2010 Jul;49(7):619-629.
[142]Yu Wang, Jisheng Li, Yan Cui, et al. Is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth through Inducing Apoptosis[J]. Cancer research,2009,69:5194.
[143]张昌明,张建龙,张琼,等.新疆汉族、维吾尔族及哈萨克族食管癌血清蛋白质指纹图谱[J].世界华人消化杂志.2010,18(17)：1173-1779.
[144]许洋.蛋白质指纹图谱技术在实验诊断与临床医学中的研究进展[J].基础医学与临床,2007,27(2)：134-142.
[145]Wulfkuhle JD, Paweltz CP, Steeg PS, et al. Proteomic approachs to the diagnosis, treatment, and monitoring of cancer [J]. Adv Exp Med Biol,2003,532:59-68.
[146]Smith FM, Gallagher WM, Fox E, et al. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy[J]. Ann Surg,2007,245(2):259-266
[147]Brockmann JG, St Nottberg H, Glodny B, et al. CYFRA 21-1 serum analysis in patients with esophageal cancer [J]. Clin Cancer Res,2000,6(11):4249-4252.
[148]Ychou M, Khemissa-Akouz F, Kralnar A, et al. A comparison of serum CYFRA21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma[J]. Cancer,2001,88(10):1023-1027.
[149]Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA21-1 determination in patients with esophageal squamons cell carcinoma:Clinical utility fo rdetection of recurrences [J]. Cancer,2000,89(7):1413-1417.
[150]Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal sqarnous cell cancer[J]. Br J Cancer,2005,93(1):107-115.
[151]Yamamoto M, Tsujinaka T, ShiozakiH, et al. Metallothionein expression correlates with the pathological response of patients with esophageal cancer underging preoperative chemoradiation therapy [J]. Oncology,1999,56(4):332-337.
[152]Matsumoto S, Yamada Y, Narikiyo M, et al. Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas[J]. Anticancer Res,2007; 27 (4B):2409-2414.
[153]Kii T, Takiuchi H, Kawabe S, et al. Evaluation of prognostic factors of esophageal squamous cell carcinoma (stagell-Ⅲ) after concurrent chemoradiotherapy using biopsy spceimens[J]. Jpn J Clin Oncol,2007,37(8):583-589.
[154]Hanunoud ZT, Badve S, Saxena R, et al. A novel biomarker for the detection of esophageal adenocarcinoma[J]. J Thorac Cardiovasc Surg,2007,133(1),82-87.
[155]Alici S, Uqras S, Bayram I, et al. Prognostic factors and COX-2 expression inadvanced stage esophageal squamous cell carcinoma[J]. Adv Ther,2006, 23(5):672-679.
[156]Jazii FR, Najafi Z, Malekzadeh R, et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer[J]. World J Gastroenterol,2006,12(44):7104-7112.
[157]Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors[J]. Int J Radiat Oncol Biol Phys,2008,72(2):398-403.
[158]An JY, Fan ZM, Zhuang ZH, et al. Proteomic analysis of blood level of proteins before and after operation in patients with esophageal squamous cell carcinoma at high-incidence area in Henan Province [J]. World J Gastroenterol,2004,10(22): 3365-3368.
[159]Zhang LY, Ying WT, Mao YS, et al. Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches[J]. World J Gastroenterol,2003,9(4):650-654.
[160]Coussens LM, Werb Z. Inflammation and cancer[J]. Nature,2002,420:860-867.
[1]Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990[J]. Int J Cancer,1999,80(6):827-841.
[2]Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990[J]. Int J Cancer,1999,83(1):18-29.
[3]段纪俊,陈万青,张思维.中国恶性肿瘤死亡率的国际比较[J].中国社会医学杂志,2009,26(6)：377-378.
[4]Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007[J]. CA Cancer J Clin, 2007,57(1):43-66.
[5]Wei JT, Shaheen N. The changing epidemiology of esophageal adenocarcinoma[J]. Semin Gastrointest Dis,2003,14(3):112-127.
[6]Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence[J]. J Natl Cancer Inst,2005, 97(2):142-146.
[7]Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years[J]. Ann Surg,2000,232(2):225-232.
[8]Whooley BP, Law S, Murthy SC, et al. Analysis of reduced death and complication rates after esophageal resection[J]. Ann Surg,2001,233(3):338-344.
[9]Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer [J]. Surg Clin North Am,2002,82(4):729-746.
[10]彭先娥,史习瞬.应用趋势面探索食管癌死亡率的地理分布特征[J].海峡预防医学杂志,2003,9(2)：66-67.
[11]王国清,魏文强,乔友林.食管癌筛查和早诊早治的实践与经验[J].中国肿瘤,2010,19(1)：4-8.
[12]王国清,郝长青,魏文强.内镜下黏膜切除术治疗早期食管癌和癌前病变长期生存率观察[J].中华消化内镜杂志,2008,25(11)：584-586.
[13]邵令方,高中人,李章才,等.204例早期食管癌和贲门癌切除治疗的远期结果[J].中华外科杂志,1993,31(3)：131-133.
[14]Wang GQ, Jiao GG, Chang FB, et al. Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening[J]. Ann Thorac Surg,2004,77(5):1740-1744.
[15]Veale RB, Thornley AL, Scott E, et al. Quantitation of autoantibodies to cytokeratins in sera from patients with squamous cell carcinoma of the oesophagus[J]. Br J Cancer,1988,58(6):767-772.
[16]刘保池,王立东,裴辉,等.食管癌肿瘤相关自身抗体检测[J].临床和实验医学杂志,2007,6(6)：3-5.
[17]Shimada H, Kuboshima M, Shiratori T, et al. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma[J]. Int J Oncol,2007, 30(1):97-103.
[18]Shimada H, Nakashima K, Ochiai T, et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma[J]. Int J Oncol,2005, 26(l):77-86.
[19]Shimada H, Takeda A, Arima M, et al. Serum p53ant ibody is auseful tumor marker in superficial esophageal squamous cell carcinoma[J]. Cancer,2000, 89(8):1677-1683.
[20]Shimada H, NABEYAY, OKAZUMIS, et al. Increased serum midkine concentration as a possible tumormarker in patients with superficial esophageal cancer[J]. Oncol Rep,2003,10(2):411-414.
[21]王永兴,苏伟,许建林,等.食管癌肿瘤标志物检测的临床应用[J].现代肿瘤学,2006,14(5)：570-571.
[22]张爱敏,焦晓青,张鹏.五项肿瘤标志物联合检测对食管癌诊治的临床评价[J].标记免疫分析与临床,2008,15(2)：65-67.
[23]陈怀霞,李育涛.多项肿瘤标志物在80例食管癌诊断中的应用分析[J].中国医药导报,2010,7(2)：181-182.
[24]杨忠信,赵松.食管癌患者围术期监测血清CEA CA125.CA199和β-HCG的临床意义[J].中国老年医学杂志,2010,30(4)：466-468.
[25]李波波,李道堂,刘曙光,等.食管癌患者血清中DKK-1的表达[J].山东大学学报(医学版),2009,47(6)：58-61.
[26]俞军,周晓明,何晓松,等.食管癌患者外周血中CK19mRNA, CYFRA21-1 TPS联合检测的临床意义[J].实用老年医学,2009,23(6)：464-469.
[27]Simeda Y, Imamura M, Watanabe G, et al. Prognostic factors of oesophageal cell carcinoma from th e perspect ive ofmolecu lar b iology[J]. Br J Cancer,1999, (8):1281.
[28]Liu YS, Yu CH, Li L, et al. Express ion of p53, p16 and cyclooxygenase-2 in esophageal can cer w ith t issue m icroarray[J]. J Dig Dis,2007,8(4):222.
[29]靳玉兰,张伟,刘伯齐,等.食管癌前病变及原位癌组织中Ki67, P53, iNOS的 异常表达[J].中华肿瘤杂志,2001,23(2)：129-131.
[30]毛友生,赵晓航,张德超,等.食管癌肿瘤标志物研究进展[J].世界华人消化杂志,2002,10(11)：1321-1323.
[31]Shimada H, Okazumi S, Takeda A, et al. Presence of serum p53antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer[J]. Surg Today,2001,31(7):591-596.
[32]Takahashi K, Miyashita M, Nomura T, et al. Serum p53antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma[J]. Dis Esophagus,2007,20(2):117-122.
[33]Ewen ME, Sluss HK, Sherr CJ, et al. Functional interact ions of the ret inob lastoma protein with mammalian D-type cyclines[J]. Cell,1993,73(3):487-497.
[34]Sorsdah 1K, Casson AG, Troster M, et al. P53and ras gene expression in human esophageal cancer and Barrentts epitheliumra prospective study[J]. Cancer Dete and Prev,1994,18(3):179-185.
[35]刘莺,李克,刘文静,等DAPK mRNA和蛋白在食管鳞癌组织中的表达及意义[J].世界华人消化杂志2009,17(31)：3218-3222.
[36]王皓,钟理,王建飞,等.肿瘤标志物在食管鳞状细胞癌中的研究与应用[J].世界华人消化杂志,2009,17(18)：1842-1848.
[37]祁敏,魏显招,吴爱群.食管癌的表观遗传学与防治研究进展[J].医学研究杂志,2009,38(11)：20-23.
[38]Tycko B. Epigenetic gene silencing in cancer [J]. J Clin Invest, 2000,105(4):401-407
[39]Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation:a fundamental aspect of neoplasia[J]. Adv Cancer Res,1998,72:141-196
[40]Ehrlich M. DNA methylation in cancer:too much, but also too little[J]. Oncogene, 2002,21(35):5400-5413.
[41]Guo M, Ren J, House MG, et al. Accumulation of promotermethylation suggests epigenetic progression in squamous cell carcinoma of the esophagus[J]. Clin Cancer Res,2006,12(15):4515-4522.
[42]Guo M, House MG, Akiyama Y, et al. Hypermethylation of the GATA gene family in esophageal cancer[J]. Int J Cancer,2006,119(9):2078-2083.
[43]Bian YS, OsterheldMC, Fontolliet C, et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neop lastic progression in Barrett's esophagus[J]. Gastroenterology,2002,122(4):1113-1121.
[44]GuoM, HouseMG, Suzuki H, et al. Ep igenetic silencing of CDX2 is a feature of squamous esophageal cancer[J]. Int J Cancer,2007,121 (6):1219-1226.
[45]Abbaszadegan MR, Raziee HR, Ghafarzadegan K, et al. Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma[J]. Int J Gastrointest Cancer,2005,36(1):47-54.
[46]Tzao C, Hsu HS, Sun GH, et al. Promotermethylation of the hMLH1 gene and p rotein exp ression of human mutL homolog 1 and human mut S homolog 2 in resected esophageal squamous cell carcinoma[J]. J Thorac Cardiovasc Surg,2005, 130(5):1371.
[47]Kuroki T, Trapasso F, Yendamuri S, et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FH IT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma[J]. Cancer Res, 2003,63(13):3724-3728.
[48]Smith E, Drew PA, Tian ZQ, et al. Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation[J]. Mol Cancer,2005,13(4):42.
[49]Guo M, House MG, Akiyama Y, et al. Hypermethylation of the GATA gene family in esophageal cancer[J]. Int J Cancer.2006,119(9):2078-83.
[50]Tokugawa T, Sugihara H, Tani T, el al. Modes of silencing of p16 in development of esophageal squamous cell carcinoma[J]. Cancer Res,2002,62(17):4938-4944.
[51]Abbaszadegan MR, Raziee HR, Ghafarzadegan K, et al. Aberrant p16 methylation, a possible epigenetic risk factor in fam ilial esophageal squamous cell carcinoma[J]. Int JGastro intes t Cancer,2005,36(1):47-54.
[52]Ling Y, Huang G, Fan L, et al. CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma[J]. J Clin Pathol.2011,64(3):246-51.
[53]肖志平,刘冉,许婧,等.DNA修复酶基因MGMT启动子区异常甲基化与食管癌的关系[J].癌变.畸变.突变,2009,21(2)：105-108.
[54]Kim YT, Park JY, Jeon YK, et al. Aberrant promoter CpG island hypeanethylation of the adenanatosis polyposis coli gene can serve as a good pmgnostic factorhy affectnig lymph nodemetastasis in squamous cell carcinoma a of the espphagus[J]. Dis Esophagus,2009,22(2):143-150.
[55]Zare M, Jazii FR, Alivand MR, et al. Qualitative analysis of Adenomatous Polyposis Coli promoter:hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker[J]. BMC Cancer,2009,9:24.
[56]缪辉来,杜水洁,林木生,等.原发性肝细胞癌中错配修复基因hMLHl的表达及其意义[J].中华实验外科杂志,2005,22：435-436.
[57]Kane MH, Loda M, Gaida GM, et al. Methylation of the hMLHl promoter correlates with lack of expression of hMLHl in sporadic colon tumors and mismatch repair-defectiee human tumor cell lines[J]. Cancer Res, 1997,57(5):808-811.
[58]Yao Y, Tao H, Kim JJ, et al. Alterations of DNA mismatch repair proteins and microsatellite instability levels in gastric cancer cell lines[J]. Lab Invest, 2004,84(7):915-922
[59]Vasavi M, Kiran V, Ravishankar B, et al. Microsatellite instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers[J]. Cancer Biomark,2010,7(1):1-10.
[60]丛德刚,王胜发.食管癌组织RASSF1A基因启动子区甲基化检测及其临床意义[J].中华医学杂志,2007,87(41)：2932-2934.
[61]Lee OJ, Schneider-Stock R, McChesney P A, el al. Hypermethylalion and Loss of expression of glutathione peroxidase-3 in Barren's tumorigenesis[J]. NeopLasia, 2005,7(9):854-861.
[62]Tzao C, Sun GH, Tung HJ, et al. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma[J]. Ann Thorac Surg.2006,82(2):396-401.
[63]Dutsch-wicherek M, Sikora J, Tomaszewska R. The possible biological role of metallothionein in apoptosis[J]. Front Biosci,2008,13(9):4029-4038.
[64]Smith E, Drew PA, Tian ZQ, et al. Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation[J]. Mol Cancer,2005,4:42.
[65]田子强,刘俊峰,张月锋,等.食管鳞状细胞癌中MT-3基囚GpG岛甲基化及其临床意义[J].实用肿瘤杂志,2004,19(5)：386-389.
[66]田子强,李勇,刘俊峰,等.食管癌新鲜肿瘤组织中MT-3基因CpG岛甲基化的临床意义[J].中国肿瘤临床,2008,35(20)：1180-1183.
[67]解明然,林鹏.蛋白质组学及其在食管癌中的应用[J].国际肿瘤学杂志,2009,36(12)：437-439.
[68]刘茶珍,朱佩云,施民新,等.表达蛋白质组学技术及其在食管癌研究中的进 展[J].环境与职业医学,2006,23(2)：158-160.
[69]张昌明,伊力亚尔.夏合丁,张建龙.蛋白质组学技术及其在食管癌中的研究进展[J].新疆医科大学学报,2010,33(2)：212-214.
[70]Enzinger PC, Mayer RJ. Esophageal cancer[J]. N Engl J Med,2003,349(23):2241-2252.
[71]Xiong XD, Xu LY, Shen ZY, et al. Identification of differentially expressed proteins between human esophageal immortalized andcarcinomatous cell 1 ines by two dimensional electrophoresis and MALDI-TOF-MS[J]. World J Gastroenterol, 2002,8(5):777-781.
[72]Xiong XD, Li EM, Xu LY, et al. Separation and identification of differentially expressed nuclear matrix proteins between human esophageal immortalized and carcinomatous cell lines[J]. World J Gastrognterol,2003,9(10):2143-2148.
[73]Qi YJ, He QY, Ma YF, et al. Proteomic identification of malignant transformation related proteins in esophageal squamous cell carcinoma[J]. J Cell Biol,2008,104 (5):1625-1635.
[74]牛保华,齐义军,曹世华,等.食管鳞癌恶性表型相关蛋白的蛋白质组学研究[J].肿瘤,2009,29(7)：611-615.
[75]Ostrowski J, Mikula M, Karczmarski J, et al. Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics[J]. J Mol Med,2007, 85(7):733-743.
[76]Flucke U, Steinborn E, Dries V, et al. Immunoreactivity of cytokeratins(CK7, CK20) and mucin peptide core antigens(MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach[J]. Histopathology,2003,43(3): 127-134
[77]Ormsby AH, Goldblum JR, Rice TW, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach[J]. Human Pathol,1999,30(3):288-294.
[78]Liu Z, Feng JG, Tuersun A, et al. Proteomic identification of differentially-expressed proteins in esophageal cancer in three ethnic groups in Xinjiang[J]. Mol Biol Rep,2010 Dec 2.[Epub ahead of print]
[79]Emmert-Buck MR, Gillespie JW, Paweletz CP, et al. An approach to proteomics analysis of human tumors[J]. Mol Carcinog,2000,27(3):158-165.
[80]Zhou G, Li HM, Gong Y, et al. Proteomic analysis of global alteration of protein expression in squamous cell carcinoma of the esophagus[J]. Proteomics,2005, 5(14):3814-3821.
[81]汪斌,李俊材,傅仲学,等.食管鳞癌淋巴结转移的蛋白质组分析[J].重庆医科大学学报,2008,31(5)：587-591.
[82]Tutuian R. Update in the diagnosis of gastroesophageal reflux disease[J]. J Gastrointestin Liver Dis,2006,15(3):243-247.
[83]Zhao J, Chang AC, Li C, et al. Comparative proteomics analysis of Barrett Metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping[J]. Mol Cell Proteomics,2007,6(6):987-999.
[84]任涛,胡建明,刘春霞,等RASSF1A基因启动子甲基化与新疆哈萨克族食管癌的相关性研究[J].农垦医学,2009,31(6)：481-486.
[85]Liotta LA, Petricoin EF. Serum peptidome for cancer detection:spinning biologic trash into diagnostic gold[J]. J Clin Invest,2006,116(1):26-30.
[86]Zhang H, Liu AY, Loriaux P, et al. Mass spectrometric detection oft issue proteins in plasma[J]. Mol Cell Proteomics,2007,6(1):64-71.
[87]Liu LH, Shan BE, Tian ZQ, et al. Potential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry[J]. Clin Chem Lab Med,2010,48(6):855-861.
[88]任兴军,谭小林,杨成虎,等.食管癌血清蛋白质谱指纹图分析及人工神经网络诊断模型研究[J].现代检验医学杂志,2010,25(3)：22-26.
[89]谭小林,王开正,胡琼英,等.食管癌血清蛋白质谱指纹图分析及人工神经网络诊断模型研究[J].现代检验医学杂志,2010,25(3)：27-30.
[90]刘丽华,单保恩,王士杰,等.食管癌患者血清蛋白指纹图谱的检测及食管癌诊断模型的建立[J].中国肿瘤生物治疗杂志,2009,16(3)：272-276.
[91]单探幽,冯笑山,王立东,等.责门癌蛋白质组与病理分化程度的研究[J].中华肿瘤防治杂志,2007,14(5)：373-376.
[92]徐淑永,张琼,张朝霞,等.新疆维吾尔族食管癌患者血清蛋白指纹图谱诊断模型的建立[J].新疆医科大学学报,2008,31(2)：154-156.
[93]Xu SY, Liu Z, Ma WJ, et al. New potential biomarkers in the diagnosis of esophageal squamous cell carcinoma[J]. Biomarkers,2009,14(5):340-6.
[94]张昌明；张建龙；张琼,等.新疆汉族、维吾尔族及哈萨克族食管癌血清蛋白质指纹图谱[J].世界华人消化杂志,2010,18(17)：1773-1779.
[95]Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research:practical advices[J]. Expert Rev Proteomics,2007,4(1):51-65.
[96]Finn OJ. Immune response as a biomarker for cancer detection and a lot more[J]. N Engl J Med,2005,353(12):1288-1290.
[97]Fujita Y, Nakanishi T, Miyamoto Y, et al. Proteomics_based identification of autoantibody against heat shock protein 70 as a diagnost ic marker in esophageal squamous cell carcinoma[J]. Cancer Lett,2008,263(2):280-290.
[98]Fujita Y, Nakanishi T, Hiramatsu M, et al. Proteomics based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma[J]. Clin Cancer Res,2006,12(21):6415-6420.
[99]Fu L, Qin YR, Xie D, et al. Identificat ion of alpha-actinin 4 and 67kDa laminin receptor as stage_specific markers in esophageal cancer via proteomic app-roaches[J]. Cancer,2007,110(12):2672-2681.
[100]安继业,秦艳茹,庄则豪,等.河南食管癌高发区同一患者食管癌手术前后血清蛋白质组变化分析[J].中国综合临床,2006,22(11)：1026-1028.
[101]Cai Z, Zhou Y, Lei T, et al. Mammary serine protease inhibitor inhibits epithelial growth factor induced epithelial esenchymal transition of esophageal carcinoma cells[J]. Cancer,2009,115(1):36-48.
[102]Jazii FR, Najafi Z, Malekzadeh R, et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer[J]. World J Gastroenterol,2006,12(44):7104-7112
[103]Uemura N, Nakanishi Y, Kato H, et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics[J]. Int J Cancer,2009, 124(9):2106-2115.
[104]Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics[J]. Biomarker Insights,2006,2(1):1-48.
[105]Harris L, Fritsche H, Mennel R, et al. Americian Society of Clinical Oncology 2007 update of recommendat ions for the use of tumor markers in breast cancer[J]. J Clin Oncol,2007,25(33):5287-5312.
[106]Vallbohmer D, Brabender J, Metzger R, et al. Genetics in the pathogenesis of esophageal cancer:possible predictive and prognostic factors[J]. J Gastrointest Surg.2010,14 Suppl 1:S75-80.